REVIEW article

Front. Pharmacol., 27 April 2023

Sec. Pharmacology of Anti-Cancer Drugs

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1172939

Antitumor effects and potential mechanisms of aconitine based on preclinical studies: an updated systematic review and meta-analysis

  • 1. State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

  • 2. State Key Laboratory of Southwestern Chinese Medicine Resources, Research Center for Academic Inheritance and Innovation of Ethnomedicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

  • 3. State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China

Abstract

Background: Herbs originating from the Aconitum L. (Ranunculaceae), such as Aconitum carmichaelii Debeaux. (Wutou), Aconitum pendulum Busch. (Tiebangchui), and Aconitum kusnezoffii Reichb. (Caowu), etc. are highly valued for their medicinal properties. The roots and tubers of these herbs are commonly used to treat an array of ailments, including joint pain and tumors. The alkaloids present in them are the primary active components, with aconitine being the most notable. Aconitine has gained attention for its exceptional anti-inflammatory and analgesic properties, as well as its potential as an anti-tumor and cardiotonic agent. However, the exact process through which aconitine hinders the growth of cancerous cells and triggers their programmed cell death remains unclear. Therefore, we have undertaken a comprehensive systematic review and meta-analysis of the current research on the potential antitumor properties of aconitine.

Methods: We conducted a thorough search of relevant preclinical studies in databases including PubMed, Web of Science, VIP, WanFang Data, CNKI, Embase, Cochrane Library, and National Center for Biotechnology Information (NCBI). The search was conducted up until 15 September 2022, and the data were statistically analyzed using RevMan 5.4 software. The number of tumor cell value-added, tumor cell apoptosis rate, thymus index (TI), and Bcl-2 gene expression level were the main indicators to be analyzed.

Results: After applying the final inclusion criteria, a total of thirty-seven studies, comprising both in vivo and in vitro research were analyzed. The results showed that treatment with aconitine led to a significant reduction in tumor cell proliferation, a noteworthy increase in the rate of apoptosis among tumor cells, a decrease in the thymus index, and a reduction in the expression level of Bcl-2. These results suggested that aconitine could inhibit the proliferation, invasion, and migration abilities of tumor cells by regulating Bcl-2 etc., thereby enhancing the anti-tumor effects.

Conclusion: In summary, our present study demonstrated that aconitine effectively reduced tumor size and volume, indicating a strong anti-tumor effect. Additionally, aconitine could increase the expression levels of caspase-3, Bax and other targets. Mechanistically, it may regulate the expression levels of Bax and Bcl-2 through the NF-κB signaling pathway, ultimately inhibiting tumor cell proliferation through autophagy.

1 Introduction

A malignant tumor refers to a vast array of diseases that are characterized by the loss of normal cellular regulation, uncontrolled growth, abnormal differentiation, local tissue infiltration, and distant transplantation (Reardon, 2010). Malignant tumors can develop in any tissue of any organ and can occur at any age (). The International Agency for Research on Cancer (IARC) of the World Health Organization has released the latest global cancer burden data, revealing that there will be 19.29 million new cancer cases worldwide in 2020. Shockingly, 4.57 million of these cases will be in China, accounting for 23.7% of the new global cancer cases. To make matters worse, both the number of cancer deaths and the number of new cancers globally rank first in the world (Zhang, 2021). In the field of oncology, there are several options available to treat malignant tumors. These include surgery, radiotherapy (), chemotherapy, immunotherapy, targeted therapy (), endocrine therapy (Reinbolt et al., 2015), stem cell transplantation (), and DNA precision therapy (Raimundo et al., 2021). However, two of the most commonly used treatments, chemotherapy and radiotherapy, often come with a range of side effects (Tommelein et al., 2018), such as damage to local radiation areas, hair loss, nausea and vomiting, fever, and impaired hematopoietic function. Additionally, oral drugs used in treatment can also lead to reduced patient wellbeing due to associated side effects (Lin et al., 2017; ). With targeted therapy, the required drugs are taken for a long time and the specific drugs are expensive. Therefore, it is crucial to find alternative drugs for the treatment of malignant tumors. The current treatment modalities for malignancies are shown in Figure 1A. Chinese herbal medicine has become a Frontier area of oncology drug research because of its lesser side effects and unique pharmacological activities. More and more scholars have started to search for natural products with antitumor efficacy from herbal medicines.

FIGURE 1

Medicinal materials derived from Aconitum L., including Aconitum carmichaelii Debeaux. (Wutou), Aconitum brachypodum Diels. (Xueshangyizhihao), Aconitum coreanum (H. Lév.) Raipaics. (Huanghuawutou), Aconitum kusnezoffii Reichb. (Caowu), and Aconitum pendulum Busch. (Tiebangchui), etc. are well-known Chinese herbal medicines. It is reported to be widely used in many traditional medical systems, including Chinese, Tibetan, Mongolian, and Indian medicine. Modern pharmacological research has confirmed their analgesic and anti-tumor effects, which has sparked interest among scholars in the field of oncology (Ma et al., 2015; ) (Figure 2). Aconitine (C34H47NO11) is a C19-diterpenoid alkaloid that possesses good anti-tumor effects and is the main medicinal ingredient in Aconitum medicinal materials (Yang et al., 2016) (Figure 1B). Clinically, aconitine is mostly used to prevent and treat cancer, including pancreatic cancer (), ovarian cancer (Li et al., 2018), breast cancer (), lung cancer (Zhang et al., 2020), liver cancer (Qi et al., 2018a; Yao et al., 2021) and melanoma (), etc. Its action mechanism is primarily to induce apoptosis, inhibit cancer cell proliferation and migration (; Wang et al., 2020; Wang et al., 2022), etc. In addition, it is also used for local anesthesia (), analgesia (Wang et al., 2008), anti-inflammation (Zheng et al., 2017), and sweating (Wu et al., 2021; Zhang et al., 2021). Aconitine has shown excellent efficacy in anti-inflammation, for instance, in the treatment of rheumatoid arthritis, by regulating IL-6 and TNF-α cytokine levels and inhibiting the activation of NF-κB signaling pathway (). Currently, several animal and cellular experiments have confirmed the inhibitory effect of aconitine alkaloids on malignant tumors (Yao et al., 2021; Li et al., 2022). As shown above, aconitine shows powerful antitumor potential in a variety of tumors and has good prospects for development and application.

FIGURE 2

Although aconitine has anti-inflammatory and analgesic properties, improper use can result in severe cardiac arrhythmias, shock, and coma (). This is because aconitine affects voltage-sensitive sodium channels in excitable tissues such as cardiac muscle, nerve, and muscle, leading to cardiotoxicity and neurotoxicity (Yang et al., 2021; ; ). Furthermore, studies in recent years have also shown that aconitine can cause embryotoxicity (), nephrotoxicity (), hepatotoxicity (), and reproductive toxicity (Wang et al., 2019). Numerous preclinical studies have demonstrated that aconitine has a notable inhibitory effect on malignant tumors. However, these results originate from various laboratories and users, which may result in some inaccuracies. As a result, it is essential to integrate and analyze the study outcomes using appropriate methods.

Systematic review is a highly effective method of producing dependable information that can serve as the most authoritative form of medical evidence. According to the Oxford Center for Evidence-Based Medicine grades of evidence, only data from systematic reviews can be recognized as 1A evidence (). As a generally accepted and effective method, the search for aconitine’s extensive preclinical evidence of inhibiting malignant tumors and promoting apoptosis of malignant tumor cells in vitro and in vivo can help expand the clinical application of aconitine and the subsequent development of related anticancer drugs. In this study, a systematic evaluation and meta-analysis of aconitine’s antitumor properties were conducted for the first time. This involved searching both domestic and international literature databases to identify relevant preclinical literature and to determine the anti-tumor mechanism of aconitine. The aim was to provide a systematic evaluation that would serve as an evidence-based foundation for subsequent anti-tumor research on aconitine.

2 Materials and methods

2.1 Protocol

This meta-analysis strictly adhered to the protocol registered in PROSPERO (CRD42022370809) and followed the PRISMA guidelines.

2.2 Retrieval strategy

In this subject paper, we utilized various computerized search databases such as WanFang Data, CNKI, VIP, PubMed, Embase, Web of Science, and Cochrane Library. The search period was limited to the date of creation up to 15 September 2022. Additionally, to ensure that we did not miss any relevant articles, we conducted a manual search of the retrieved articles.

2.2.1 Chinese database retrieval strategy

The Chinese literature search was conducted through the following search strategy: ① “aconitine” or “aconitine alkaloid”; ② “anti-cancer” or “anti-tumor” or “anti-proliferation” or “anti-proliferative” or “anti-proliferative activity” or “inhibition of cell proliferation”; ③ “cancer cell” or “tumor cell”; ④ including ①②③ and other subject words or free words.

The search strategy for Chinese literature involved the following steps: ①, searching for keywords “aconitine” or “aconitine alkaloid”; ②, looking for terms such as “anti-cancer” or “anti-tumor” or “anti-proliferation” or “anti-proliferative” or “anti-proliferative activity” or “inhibition of cell proliferation”; ③, searching for phrases like “cancer cell” or “tumor cell”; ④, including ①②③ along with other relevant subject words or free words.

2.2.2 English database retrieval strategy

To search for English literature on the topic, the following strategy was employed: ①, Keywords such as “Aconitine” or “Aconitum alkaloid” or “Aconitine alkaloids” were used; ②, Terms such as “Anticancer” or “Antitumor” or “Antiproliferative” “Anti-proliferation” or “Antiproliferative activity” were included; ③, Phrases like “Cancer cell” or “Tumor cell” were also added; ④, All the above terms were combined using “OR” and “AND” to form a comprehensive search group. In addition, other relevant subject words and free words were included.

These were the techniques we used to conduct our literature searches: [“aconitine” (MeSH Terms) OR “aconitine” (All Fields)] OR [“aconitum” (MeSH Terms) OR “aconitum” (All Fields)] AND [“alkaloids” (MeSH Terms) OR “alkaloids” (All Fields) OR “alkaloid” (All Fields)] OR [“aconitine” (MeSH Terms) OR “aconitine” (All Fields)] AND [“alkaloids” (MeSH Terms) OR “alkaloids” (All Fields)] AND [Anticancer (All Fields) OR Antitumor (All Fields) OR Antiproliferative (All Fields) OR Anti-proliferation (All Fields)] OR [Antiproliferative (All Fields)] AND [“motor activity” (MeSH Terms)] OR [“motor” (All Fields) AND “activity” (All Fields)] OR [“motor activity” (All Fields) OR “activity” (All Fields)] AND [“cancer” (All Fields) AND “cell” (All Fields)] OR [“cancer cell” (All Fields)] OR [“tumour” (All Fields) OR “neoplasms” (MeSH Terms) OR “neoplasms” (All Fields) OR “tumor” (All Fields)] AND [“cells” (MeSH Terms) OR “cells” (All Fields) OR “cell” (All Fields)].

2.3 Literature inclusion and exclusion criteria

2.3.1 Inclusion criteria

1) Study: Aconitine inhibits malignant tumor cell proliferation and promotes tumor cell apoptosis related article. 2) The experimental group received aconitine monotherapy without regard to treatment method, dose and frequency. 3) The control group was given only saline, pure water or no adjuvant intervention. 4) Outcome indicators: the main outcome indicators included tumor weight, tumor cell inhibition rate (IR), tumor cell apoptosis rate, thymus index (TI), and degree of apoptotic invasion, which encompassed at least one of the above indicators.

2.3.2 Exclusion criteria

1) The target disease was not malignancy, cancer, etc.; 2) There was no control group; 3) The trial group received a combination of aconitine; 4) Duplicate published literature; 5) Studies were clinical studies, case reports, clinical trials, reviews, conference papers, abstracts, reviews, and patent results; 6) Unpublished dissertations; and 7) Literature for which data could not be extracted.

2.3.3 Literature screening and data extraction

Two investigators conducted literature screening and data extraction independently, utilizing Endnote and adhering to the aforementioned inclusion and exclusion criteria. The extracted data will be organized using Excel software and cross-checked for accuracy. In the event of any discrepancies, a joint decision will be made after consulting with a third researcher. Further details regarding the data extraction process can be found below: 1) The first author and year of publication of the literature; 2) Individual data of the experimental study, such as animal species, sex, body weight, and individual comparison samples; 3) The type of anesthesia; 4) The intervention characteristics of the treatment and control groups, including drug dosage form, dose, treatment method, and frequency of administration; and 5) The mean, standard deviation, and between-group differences of measurements and corresponding data.

2.3.4 Quality evaluation of included documents

Two authors conducted independent assessments of the methodological quality of the studies included in this paper. The assessments were based on the CAMARADES list, which provides a collaborative approach to meta-analysis and review of animal data from experimental studies. The list comprises 10 items (Sena et al., 2007): ①Publication of the paper after peer review; ② Description of temperature control; ③ Randomization to treatment and control groups; ④ Blinding of the model; ⑤ Blinded assessment of the results; ⑥ No intrinsic neuroprotective effect of the use of anesthetics; ⑦ Appropriate animal models; ⑧ Sample size calculation; ⑨ Compliance with animal protection regulations, and ⑩ Declaration of any potential conflicts of interest. Each project was rated for overall quality using a single-point system. In the event of any discrepancies in the quality assessment, a third investigator was consulted to resolve them.

2.3.5 Statistical methods

Meta-analysis was performed by using Review Manager 5.4 software. Odds ratios (OR) were used to express count data as statistical effect sizes, while mean difference (MD) was used to express continuous variables. To ensure accuracy, all effect sizes were accompanied by a 95% confidence interval (CI). Heterogeneity was evaluated using Higgins I2, and when the results of the heterogeneity test were not statistically significant (p > 0.05, I2 ≤ 50%), a fixed-effects model was employed for meta-analysis, However, if I2 > 50%, a heterogeneity test was required to identify the cause of heterogeneity. If heterogeneity remained above 50% after sensitivity analysis or subgroup analysis, only a description of the results was required. The results were considered statistically significant with a p-value of p < 0.05. Meta-analysis test level was a = 0.05, and publication bias was expressed using funnel plots.

3 Results

3.1 Study inclusion

Based on the search method described above, a total of 2581 documents were initially searched. After removing 407 duplicate documents, 2174 articles remained. Of these, 1606 articles were excluded as they were reviews, experiences, conferences, patents, or results, leaving 568 articles after the initial screening. After reviewing the titles and abstracts of these articles, 450 papers were found to have inconsistent contents and were excluded, resulting in a final selection of 118 papers. After reading the full text, we excluded several papers. Specifically, we excluded 21 papers that were reviewed, 36 papers that involved combined drug interventions in both the treatment and control groups, 21 papers from which we were unable to extract experimental data, 2 clinical papers, 8 papers that were tested with drugs other than aconitine alkaloids, and 30 papers that studied diseases other than antitumor. Ultimately, we included 37 literatures for analysis. The screening process is shown in Figure 3. Included literature is shown in Table 1.

FIGURE 3

TABLE 1

No.AuthorTimeSource/NatureExperiment type (animal/cell)Tumor/Cell typeDatabase sourcesRef.
1Tang et al.1986UnknownCell ExperimentStomach CancerCNKITang and Sun (1986)
2Yang et al.2005UnknownAnimal and Cell ExperimentLung CancerCNKI, WanFang, VIPYang et al. (2005)
3Zeng et al.2007UnknownAnimal and Cell ExperimentLoVo, MGC-803, S180 tumor cellsCNKI, WanFang, VIPZeng et al. (2007)
4Ren et al.2008FuziAnimal ExperimentLiver CancerCNKI, VIPRen and Zeng (2008)
5Wu et al.2008Folium Aconiti Kusnezoffii ReichbAnimal ExperimentMonocyte-macrophageCNKI, WanFang, VIPWuliji et al. (2008)
6Xu et al.2008Aconitum vaginatum PritzCell ExperimentS180 tumor cellsCNKI, WanFang, VIPXu et al. (2008)
7Zhu2008Aconitum vaginatum PritzCell ExperimentGastric cancer, Liver cancer, Lung cancerCNKI, WanFangZhu (2008)
8Rao et al.2010UnknownCell ExperimentRetinal nerve cellsCNKI, WanFangRao and Peng (2010)
9Jia et al.2011UnknownCell ExperimentStomach CancerCNKI, WanFang, VIP
10Zhang et al.2011FuziCell ExperimentStomach CancerCNKI, WanFang, VIPZhang and Wu (2011)
11Ding et al.2013FuziCell ExperimentStomach CancerCNKI, WanFang, VIP
12Liu2013Aconitum leucostomum WoroschCell ExperimentLeukemia K562 cellsCNKI, WanFangLiu (2013)
13Ding2014FuziCell ExperimentStomach CancerCNKI
14Hao2014Aconitum flavum HandCell ExperimentGastric cancer, Liver Cancer, Lung cancerCNKI, WanFang
15Zhao et al.2014UnknownAnimal and Cell ExperimentLung CancerCNKI, VIPZhao et al. (2014)
16Fan et al.2015Aconitum szechenyianum GayCell ExperimentKidney cellsPubMed, Embase, Web of Science
17Guan et al.2015UnknownCell ExperimentLeukemia K562 cellsCNKI, WanFang, VIP
18Ji et al.2016UnknownAnimal and Cell ExperimentPancreatic CancerPubMed, Embase
19Guan et al.2017UnknownCell ExperimentLeukemia K562 cellsCNKI, WanFang, VIP
20Ma2017UnknownCell ExperimentLung CancerCNKI, WanFangMa (2017)
21Zhang et al.2017UnknownAnimal ExperimentLung CancerPubMed, Embase, Web of ScienceZhang et al. (2017)
22Ma et al.2018UnknownCell ExperimentMyeloma cellsCNKI, WanFang, VIPMa and Yu (2018)
23Qi et al.2018UnknownAnimal and Cell ExperimentLiver CancerPubMed, Web of ScienceQi et al. (2018b)
24Wu et al.2018UnknownAnimal and Cell ExperimentBreast CancerPubMed, Embase, Web of ScienceWu et al. (2018)
25Xiong et al.2018UnknownCell ExperimentLiver CancerCNKI, WanFang, VIPXiong et al. (2018)
26Zhang et al.2018FuziCell ExperimentH9c2 tumor cellsCNKI, WanFang, VIPZhang et al. (2018)
27Cheng2019UnknownAnimal and Cell ExperimentStomach CancerCNKI
28Shao et al.2019UnknownCell ExperimentLung CancerCNKI, WanFang, VIPShao et al. (2019)
29Zhou et al.2019UnknownCell ExperimentEsophageal CancerCNKI, WanFang, VIPZhou et al. (2019)
30Cheng et al.2020FuziCell ExperimentRegulation of T cellsCNKI, WanFang, VIP
31Ru et al.2020UnknownCell ExperimentStomach CancerCNKI, WanFang, VIPRu et al. (2020)
32Wang2020UnknownAnimal ExperimentLiver CancerCNKI, WanFangWang (2020)
33Wang et al.2020UnknownCell ExperimentOvarian CancerPubMed, Web of ScienceWang et al. (2020)
34Zhang et al.2020UnknownCell ExperimentLung CancerCNKI, VIPZhang et al. (2020)
35Zou et al.2021UnknownCell ExperimentOsteosarcoma cellsCNKI, WanFang, VIPZou et al. (2021)
36Cai2022UnknownCell ExperimentProstate CancerCNKI, WanFang, VIP
37Luan et al.2022UnknownAnimal and Cell ExperimentBreast CancerPubMed, EmbaseLuan et al. (2022)

Inclusion of literature information.

Note, Fuzi is the root of Aconitum carmichaelii Debeaux. (Wutou).

3.2 Basic characteristics of included literature

The subject paper included thirty-seven preclinical studies, which could be classified into five animal experiments, twenty-four cellular experiments, and eight experiments that involved both animal and cellular testing. The animal experiments involved a combination of male and female animals in four studies, while eight studies used only male animals and one study used only female animals. Additionally, thirteen animal studies provided information on the body weight of the animals. Eight studies did not report the method of animal execution, while four studies utilized decerebrate execution and one study used 0.1 mL of 1% pentobarbital solution for anesthetic execution. The dosing time ranged from a minimum of 5 days to a maximum of 26 weeks. In terms of cellular experiments, fifteen studies mentioned the cell inhibition rate or cell proliferation inhibition rate. Sixteen studies reported on apoptosis rate, while six studies focused on detecting rate OD or absorbance A value. Additionally, five studies provided insight into different cell cycle numbers, while six studies explored cell invasion ability, cell invasion inhibition rate, or cell invasion number. Furthermore, twelve studies delved into the expression levels of proteins such as p21-Ras, p38MAPK, p53, Bcl-2, Bax, and others. The detailed characteristics of the included studies are shown in Table 2 and Table 3.

TABLE 2

LiteratureObjectsWeightAnaesthesiaGrouping and administrationResultMechanismDifference between groups
Tang and Sun (1986)C57BL, Kunming mice, both18–22 gNRControl group: normal saline①FC for gastric cancer: ↓ tumor weight____p < 0.01 (0.4 mg/mL)
Aconitine group: 0.2, 0.1, 0.05, 0.4 mg/mL②↓ tumor weight (sarcoma S180)p < 0.05 (0.2 mg/mL)
Administration time: 14 d③spontaneous metastasis of LLC: ↓ tumor weightp < 0.001 (0.4 mg/mL)
Yang et al. (2005)C57 mice, male (SPF)18–20 gNRTumor bearing group: distilled water①↓ tumor weight____p < 0.001 (0.80 g/kg)
Normal group: distilled water②↓ thymus indexp < 0.01 (0.80 g/kg)
Aconitine group: 0.51, 0.64, 0.80 mg/kg③↓ number of metastasesp < 0.001 (0.51, 0.64 g/kg), p < 0.01 (0.80 g/kg)
Administration time: 18 d
Zeng et al. (2007)Kunming mice, both (SPF)18–22 gCervical dislocationModel group: normal saline①↓ tumor weight____p < 0.01 (60 g/kg)
Aconitine group: 0.15, 0.30, 0.60 mg/mL
Administration time: 10 d
Wu et al. (2018)ICR mice, both20 ± 2 gNRControl group: distilled water①↑ mononuclear macrophage phagocytosis____p > 0.05 (50, 100, 150 mg/kg)
Positive drug: Levamisole hydrochloride, 100 mg/kg② ↑serum IgG levelp < 0.01 (50, 100 mg/kg), p < 0.05 (150 mg/kg)
Aconitine group: 0.50, 1.00, 1.50 mg/kg
Administration time: 7 d
Ren and Zeng (2008)Kunming mice, male18–22 gCervical dislocationBlank group: Normal saline, 0.2 mL⑴↓ tumor weight⑴↑ TNF-α, ↓ NF-κB, ↑ caspase-3p < 0.01
Aconitine group: 2 mg/kgp < 0.05
Administration time: 10 d
Zhao et al. (2014)C57BL mice, male (SPF)20 ± 2 gNRNormal group: normal saline①↑ 10 min autonomous activity frequency____p < 0.01
Model group: 0.5% CMC-Na②↑ heart oxygen saturation, ↑ body temperature, ↓ plasma viscosityp < 0.01 (3 g/kg), p < 0.05 (1 g/kg)
Positive drug: DOX, 5 mg/kg③↑ erythrocyte ATPasep < 0.01
Aconitine group: 1 mg/kg, 3 mg/kg④↓ intratumoral/pulmonary capillary permeabilityp < 0.01
Administration time: 5 d⑤↓ tumor/lung HIF-1α, ↓ tumor weightp < 0.01
⑥↑ intratumoral/pulmonary oxygen saturationp < 0.01
⑦↓ number of pulmonary metastatic nodulesp < 0.01
Athymic nude mice, male20 ± 2 gNRModel group: methanol①↓ tumor volume____p < 0.01 (50, 100 mg/kg, 24, 28 d)
Aconitine group: 0.50, 1.0 mg/kg②↓ tumor weightp < 0.01 (50 mg/kg), p < 0.001 (100 mg/kg)
Administration time: 28 d
Ma (2017)Kunming mice, male18–22 gNRModel group: 0.5% CMC-Na①↑ body weight (10 w), → body weight (16 w)⑴↑ E-Cadherin, ↑ Cytokoratin-18, ↓ N-Cadherin, ↓ Vimentin protein expression, ↓ OCT-4, ↓ NANOG, ↓ PCNA protein expression①NR
Aconitine group: 0.2 mg/kg②↓ 5min autonomous activity②NR
Administration time: 26 w③↓ lung indexp < 0.05
④↓ number of pulmonary nodulesp < 0.01
⑴NR
Qi et al. (2018)C57BL/6J mice, female (SPF)18–22 gNRModel group: normal saline, 5 mL/kg①↓ tumor volume⑴→PD-L1 mRNA expressionp < 0.05
Aconitine group: 36.0 mg/10 g②↓ tumor weight, ↓ tumor inhibition ratep < 0.05
Administration time: 16 d③↑ apoptosis ratep < 0.05
④↑ IL-2, → IL-5, ↑ IL-6, ↑ IL-10, → IL-12, ↓ TGF-β contentp < 0.05 (Il-2, IL-6, IL-10, TGF-β)
⑤→ Treg ratio of LLC model micep > 0.05
p > 0.05
Qi et al. (2018)BALB/c nude mice, male20 ± 2 gNRControl group: PBS①↓ tumor volume____p < 0.01 (2, 4 mg/kg)
Aconitine group: 2, 4 mg/kg②↑ survival time of mice②NR
Administration time: 21 d
Wu et al. (2018)FVB mice, male20–22 gCervical dislocationControl group: 0.1% DMSO①↑ ARE fluorescein activity⑴↑ MRP2, ↑ BCRP protein expressionp < 0.001 (25, 50, 100 μM)
Aconitine group: 0.6 mg/kg⑵↑ MRP2, ↑ BCRP gene expression levelp < 0.001 (Jejunum, Ileum, Colon)
Administration time: 14 d⑶↑ Nrf2/β-actin expression ratep < 0.05 (Jejunum, Ileum, Colon)
1 ↑ MRP2, ↑ BCRP expression ratep < 0.001 (Jejunum), p < 0.01(Colon), p < 0.01 (Ileum)
p < 0.01 (Jejunum, Ileum, Colon)
615 mice, both (SPF)24 ± 2 gCervical dislocationNormal group: sterile normal saline①↓ tumor volume____p < 0.05
Model group: sterile normal saline②↓ tumor weight, ↑ tumor inhibition ratep < 0.01 (0.15 mg/mL)
Positive drug: Celecoxib, 0.5 mg/mL③↓ Treg ratio of peripheral mononuclear cells in micep < 0.01 (0.1, 0.15 mg/mL)
Aconitine group: 0.05, 0.1, 0.15 mg/mL④↓ Treg ratio of mouse spleen mononuclear cellsp < 0.01 (0.15 mg/mL)
Administration time: 14 d⑤↓ PGE2 content in peripheral blood of micep < 0.01 (0.05, 0.1 mg/mL)
⑥↑ survival time of micep < 0.05 (0.15 mg/mL)
Wang (2020)BaLB/c mice, male (SPF)20 ± 2 g0.1 mL 1% Pentobarbital solutionNormal group: sterile normal saline 0.2 mL①↑ weight, ↑ body mass⑴→ NKp46, ↓ NKG2D, ↓ TIGIT, → TACTILE expression levelp < 0.05 (0.5 mg/mL), p < 0.05 (0.5 mg/mL)
Model group: sterile normal saline 0.2 mL②↓ growth rate of subcutaneous tumor⑵↑ CD107a expressionp < 0.05
Aconitine group: 0.125, 0.25, 0.5 mg/mL, 0.2 mL③↑ tumor inhibition ratep < 0.05 (0.25 mg/mL), p < 0.01 (0.5 mg/mL)
Administration time: 21d④↑ thymus Indexp < 0.05 (0.5 mg/mL)
⑤↓ spleen indexp < 0.05 (0.25 mg/mL), p < 0.01 (0.5 mg/mL)
⑥↑ TNF-α, ↑ IL-1β, ↑ IFN-γ, → B cells, ↑ T cells contentp < 0.05 (0.5 mg/mL)
⑦↑ NK cell numberp < 0.05 (0.5 mg/mL)
p < 0.05 (0.5 mg/mL)
p < 0.05 (0.5 mg/mL)

Characteristics of included documents (Animal experiments).

TABLE 3

LiteratureCell linesGrouping and concentrationResultsMechanismDifference between groups
Yang et al. (2005)LM2 cell lineSolvent control: RPMI-1640①↑ 24 h apoptosis rate, ↑ 48 h apoptosis rate____p < 0.01 (5, 25 mg/mL, 24, 48 h), p < 0.05 (75 mg/mL, 24, 48 h)
Aconitine group: 5, 25, 75 mg/mL (24, 48 h)
Zeng et al. (2007)LoVo, MGC803 cell lineSolvent control: RPMI-1640①↓ OD value____①NR
Aconitine group: 10, 40, 80, 100, 200, 400, 600, 800 (10–3 g/mL)②↑ inhibition rate②NR
Xu et al. (2008)S180 cells were derived from Kunming miceBlank control group: RPMI-1640, cell-free①↓ absorbance A____①NR
Positive drug: 5-FU, 0.083 mg/mL②↑ tumor inhibition ratep < 0.01
Aconitine group: 0.01, 0.1, 1.0 mg/mL
Zhu (2008)AGS, HepG2 and A549 cell lineNegative control: RPMI-1640①↑ tumor inhibition rate____p < 0.05
Blank control group: normal saline, cell-free
Blank control group: 0.05% DMSO, cell-free
Positive drug: 5-FU, 100 μg/mL
Aconitine group: 0.05, 0.5, 5, 50 μg/mL
Rao and Peng (2010)Retinal nerve cells of rats were derived from SD rats and suckling ratsNegative control: 5% CO2, 20% DMEM, cell-free①↓ G0/G1 phase, ↓ S phase and ↑ G2/M phase⑴↓ p21-Ras gene and protein expressionp < 0.05
Aconitine group: 0.5%, 1 mLp = 0.036 < 0.05
Zhang and Wu (2011)SGC-7901, moderately differentiated adenocarcinoma cell lineBlank control group: RPMI-1640, cell-free①↑ tumor inhibition rate____p > 0.05 (20 mg/mL, 24 h), p < 0.05 (20 mg/mL, 48, 72 h), p < 0.05 (40, 80 mg/mL, 24, 48, 72 h)
Positive drug: 5-FU, 50 μg/mL②↑ apoptosis ratep > 0.05 (40, 80 mg/mL, 24 h)
Aconitine group: 20, 40, 80 mg/mL (24, 48, 72 h)
Liu (2013)Eca-109, MGC80-3, BGC-823, A549, NCI-H460, NCI-H446, MCF-7, SK-OV-3, A375, K-562, U937, S-180 and MHCC97-H cell linesPositive drug: DDP, 0.15, 0.75, 1.5, 5, 15, 50 μg/mL①↑ tumor inhibition rate____①NR
Aconitine group: 3, 10, 30, 100, 300, 1000 μg/mL (72 h)
SGC-7901 cell linesBlank control group: PBS, cell-free①↑ cell proliferation inhibition rate____p < 0.01 (0.05, 0.1, 0.2, 0.4, 0.8 mg/mL, 24, 48, 72 h)
Aconitine group: 0.05, 0.1, 0.2, 0.4, 0.8 mg/mL (24, 48, 72 h)②↑ apoptosis ratep < 0.05 (0.2, 0.4, 0.8 mg/mL)
③↓ G0/G1phase, ↓ G2/M phase, ↑ S phase③NR
SGC-7901 cell linesBlank control group: PBS, cell-free①↑ inhibition rate____p < 0.01 (200, 400, 800 μg/mL, 24, 48, 72 h)
Aconitine group: 50, 100, 200, 400, 800 μg/mL (24, 48, 72 h)②↓ IC50②NR
③↑ inhibition rate of cell invasionp < 0.01 (100, 200, 400 μg/mL)
④↑ early apoptosis ratep < 0.01 (100, 200, 400 μg/mL)
⑤↓ G0/G1 phase, ↓ G2/M phase, ↑ S phase⑤NR
SGC-7901, HepG2 and A549 cell linesBlank control group: RPMI-1640, cell-free①↓ OD value of cell proliferation of SGC-7901____p < 0.01 (5, 10, 50, 100 μg/mL), p < 0.05 (1 μg/mL)
Aconitine group: 1, 5, 10, 50, 100 μg/mL②↓ OD value of cell proliferation of HepG2p < 0.01 (5, 10, 50, 100 μg/mL), p < 0.05 (1 μg/mL)
③↓ OD value of cell proliferation of A549p < 0.01
Zhao et al. (2014)Lewis lung cancer cells were derived from C57BL/6 miceModel group: RPMI-1640, cell-free①↓ cell proliferation____p < 0.01
Aconitine group: 0.2、0.1、0.05、0.025 μg/mL②↓ cell adhesionp < 0.01
③↑ SDH contentp < 0.01 (0.2, 0.1 μg/mL), p < 0.05 (0.05 g/mL)
A549 cell linesNegative control: No drugs①↑ apoptosis rate⑴↑ p38 MAPK expression levelp < 0.05
Aconitine group: 100, 200, 400, 800 μg/mL②↓ ΔΨm of A549 cell⑵↑ DRS,↑ TNF-R1 expression level②NR
⑶↑ p53, ↑ Bax, ↓ Bcl-2 expression levelp < 0.05
⑷↓ expression of Cytochrome Cp < 0.05
⑸↑ cleaved caspase-9, ↓ pro-caspase-8, ↓ pro-caspase-3 expression levelp < 0.05
p < 0.05
p < 0.05
K562 cell linesBlank control group: RPMI-1640, cell-free①↑ cell proliferation inhibition rate____p < 0.05 (25, 50 mg/L, 24 h)
Solvent control: PBS②↓ number of G1 cells, ↑ number of S cellsp < 0.05 (25, 50 mg/L, 72 h)
Aconitine group: 5, 10, 25, 50, 75, 100 mg/L (24, 48, 72 h)③↑ 72 h apoptosis ratep < 0.05 (25, 50 mg/L, 72 h)
Pancreatic cancer cell lines miapaca-2 and PANC-1Negative control: No drugs①↑ tumor inhibition rate⑴↓ NF-κB, ↑ Bax, ↓ Bcl-2, ↑ cleaved caspase-9,↑ cleaved caspase-3, ↑ cleaved PARP, ↑ cyto.C protein levelp < 0.01 (30 μM)
Aconitine group: 10, 20, 40, 80 μM (24h, 48, 72 h)②↓ cell colony forming number⑵↑ caspase-3, → caspase-8, ↑ caspase-9 relative activityp < 0.05 (15, 30 μM), p < 0.01 (60 μM)
③↑ apoptosis ratep < 0.05 (30, 60 μM)
p < 0.0.5 (15, 30, 60 μM)
p < 0.05 (15, 30, 60 μM)
K562, K562 daunorubicin resistant cell linesBlank control group: RPMI-1640, cell-free①↑ K562 cell proliferation inhibition rate⑴↓ C/EBP-α, ↑ caspase-3, ↑ p53 gene expressionp < 0.05 (10, 25, 50, 75, 100 μmol/L, 24, 48, 72 h)
Solvent control: PBS②↑ K562/DNR cell proliferation inhibition ratep < 0.05 (10, 25, 50, 75, 100 μmol/L, 24, 48, 72 h)
Aconitine group: 5, 10, 25, 50, 75, 100 μmol/L (24, 48, 72 h)③↑ K562, K562/DNR apoptosis ratep < 0.05 (25, 50 μmol/L, 72 h)
p < 0.05 (50 μmol/L, C/EBP-α, Caspase-3, p53)
Ma (2017)Mouse Lewis lung cancer cells (LLC)Blank control group: DMEM, cell-free①↓ LLC cell malignant proliferation fluorescence⑴↓ Oct-4, ↓ NANOG, ↓ PCNA expression levelp < 0.05
Aconitine group: 0.1, 1, 10, 100, 1000 μg/mL (72 h)②↓ LLC cell erosion ability⑵↑ EGF, ↑ FGF, ↑ HGF, ↑ OSM, ↑ β-actin expressionp < 0.05
③↓ Cell self-renewal abilityp < 0.05
p < 0.01
p < 0.05
Ma and Yu (2018)Peripheral blood B lymphocytes of multiple myeloma (RPMI8226)Blank control group: RPMI-1640, cell-free①↑ cell proliferation inhibition rate____p < 0.05 (4, 6, 8 μmol, 12, 24, 36, 48 h)
Negative control: PBS and absolute ethanol②↑ apoptosis ratep < 0.05 (4, 8 μmol, 24, 48 h)
Aconitine group: 0.1, 0.5, 1, 10, 100 μmol/mL (24, 48 h)
Qi et al. (2018)HepG2, Huh7 and L02 cellsNegative control: No drugs①↓ cell viability⑴↑ Bax, ↓ Bcl-2, ↑ cleaved caspases-3, ↑ cleaved caspases-7, ↑ cleaved caspases-PARP, → GAPDH protein expressionp < 0.05 (6.25, 12.5 μg/mL, 24 h), p < 0.01 (6.25, 12.5, 25, 50, 100 μg/mL, 48,72 h)
Aconitine group: 6.25, 12.5, 25, 50, 100 μg/mL (24, 48, 72 h)②↑ apoptosis rate⑵↑ cytochrome c/tublin, ↓ cytochrome c/Cox IV contentp < 0.01 (25, 50 μg/mL)
③↑ ROS contentp < 0.01 (25, 50 μg/mL)
p < 0.01 (50 μg/mL), p < 0.05 (25 μg/mL)
p < 0.01 (25, 50 μg/mL)
Wu et al. (2018)human colon cancer cell line LS174T, Caco-2 Blank control group: DMSO①↓ accumulation of CDF⑴↑ MRP2, ↑ BCRP protein levelp < 0.01
Aconitine group: 5, 10, 20 μM (6,12 h)⑵↑ MRP2, ↑ BCRP expression ratep < 0.001 (Jejunum, Ileum, Colon)
⑶↑ MRP2/GAPDH, ↑ BCRP/GAPDH expression ratep < 0.01 (Colon), p < 0.05 (Jejunum, Ileum)
⑷↑ MRP2, BCRP immunofluorescence ratep < 0.01 (5, 10, 20 μM)
p < 0.05 (20 μM)
Xiong et al. (2018)Human hepatoma cell line MHCC97Blank control group: DMEM, cell-freeAconitine group: 5, 10, 20 μg/mL (96 h)①↓ proliferation number of hepatoma cells⑴↓ pP38, ↓ P38, ↓ p-MAPKAPK, ↓ p-HSP27 signal pathway expressionp < 0.05 (10, 20 μg/mL)
②↓ invasiveness of hepatoma cellsp < 0.05 (10, 20 μg/mL)
③↓ migration ability of hepatoma cellsp < 0.05 (5, 10, 20 μg/mL)
p < 0.05 (5, 10, 20 μg/mL)
Zhang et al. (2018)H9c2 cell linesBlank control group: DMSO, cell-free①↑ inhibition rate to H9c2____p < 0.05
Aconitine group: 150, 250, 400, 500, 1000 μg/mL (24 h)②↑ LDH leakage ratep < 0.05 (100, 400, 500 μg/mL)
③↑ apoptosis ratep < 0.05 (400, 500 μg/mL)
Shao et al. (2019)A549 cell linesBlank control group: RPMI-1640, cell-free①↑ cell proliferation inhibition rate⑴↓ Bcl-2, ↑ Bax, ↑ caspase-3, ↑ Beclin1, ↑ LC3, ↓ P62 mRNA expression levelp < 0.05 (100,200 μmol/L), p < 0.01 (400 μmol/L)
Aconitine group: 10, 50, 100, 200, 400 μmol/mL (24,48,72 h)②↑ 48 h apoptosis rate⑵↓ Bcl-2, ↑ Bax, ↑ active caspase-3, ↑ Beclin1, ↑ LC3 II/I, ↑ P-62 protein expression levelp < 0.01 (200, 400 μmol/L)
p < 0.05 (Beclin1, LC3 II/I, P-62, 400 μmol/L), p < 0.01 (Bcl-2, Bax, Caspase-3, 400 μmol/L)
p < 0.05 (Bcl-2, Bax, 400 μmol/L), p < 0.01 (Active caspase-3, Beclin1, LC3 II/I, P-62, 400 μmol/L)
Zhou et al. (2019)Human esophageal carcinoma EC-1 cellsBlank control group: DMEM, cell-free①↑ tumor inhibition rate⑴↓ MMP-9, ↓ Bcl-2 protein expression levelp < 0.05
Negative control: No drugs②↓ cell clonogenic abilityp < 0.05, F = 127.59 (6.25, 12.5 μg/mL)
Aconitine group: 0.8, 1.6, 3.2, 6.25, 12.5, 25.0 μg/mL (24,48,72 h)③↓ cell invasivenessp < 0.05, F = 204.34 (6.25, 12.5 μg/mL)
④↑ apoptosis indexp < 0.05, F = 428.56 (6.25, 12.5 μg/mL)
p < 0.01 (6.25, 12.5 μg/mL)
Mouse peripheral blood mononuclear cells were from 615 mice (SPF grade)Negative control: RPMI-1640, cell-free①↓ PGE2 content in monocytes of 615 mice____p < 0.05 (2 mg/mL)
Positive drug: Celecoxib, 2.5 μg/mL②↓ percentage of Tregs differentiated from monocytes in 615 micep < 0.05 (0.5 mg/mL), p < 0.01 (0.1, 2 mg/mL)
Aconitine group: 0.1, 0.5, 2 mg/mL
Human gastric adenocarcinoma SGC-7901 cell line was derived from SD ratsControl group: normal saline①↓ SGC-7901 cell proliferation____p < 0.05
Positive drug: 5-FU, 250 mg/L
Aconitine group: 1:1000 (24,48,72 h)
Ru et al. (2020)Gastric adenocarcinoma cell line MGC803Solvent control: DMEM, cell-free①↓ proliferation of gastric adenocarcinoma cells⑴↑ miR-23a expression, ↑ IRF1 gene expression levelp < 0.05
Negative control: No drugs②↓ cell colony forming abilityp < 0.05 (40 μg/mL)
Aconitine group: 5, 10, 20, 40, 60, 80, 100 μg/mL (24,48,72 h)③↑ apoptosis indexp < 0.05 (40 μg/mL)
p < 0.05 (40 μg/mL, miR-23a), p < 0.01 (40 μg/mL, IRF1)
Wang (2020)Human hepatoma cell lines Huh-7, MHCC-97h, MHCC -lm3, BEL-7402, Hep-G2, Hep -3B, SMMC-7721Blank control group: DMEM+10% FBS, cell-free①↓ OD value of hepatoma cells (48, 72 h)____p < 0.05
Negative control: No drugs②↑ apoptosis rate of hepatocellular carcinoma cellsp < 0.01 (high dose)
Aconitine group: 250, 500, 1000, 2000, 4,000, 8,000 μg/mL (24,48,72 h)③↓ migration ability of hepatoma cells③NR
Wang et al. (2020)Human oVca cell lines, a2780 and normal ovarian cell ioSe80Negative control: No drugs①↓ cell viability⑴↑ ERβ, ↓ VEFG expression levelp < 0.01 (50, 100, 200, 400, 800, 1000 μg/mL, 24 h)
Positive drug: DDP, 1, 5, 25, 50, 100 μg/mL②↓ cell colony forming number, ↓ cell invasiveness, ↓ cell migration ability⑵↓ HiF-α, ↑ PHd2, ↓ MMP2, ↓ MMP9, ↓ aTM, ↓ p-aTM, ↑ p53 expression levelp < 0.01 (100, 200, 400 μg/mL), p < 0.01 (25, 50, 100 μg/mL), p < 0.01 (100 μg/mL)
Aconitine group: 10, 50, 100, 200, 400, 800, 1000 μg/mL (6,12,24 h)③↑ ΔΨm⑶↑ Bax, ↓ Bcl-2, ↑ apaf-1, ↑ cleaved caspase-3, ↑ cleaved caspase-9, ↓ Bcl-xl, ↑ Cyt C, ↑ cleaved ParP protein expression levelp < 0.01 (400 μg/mL), p < 0.05 (100, 200 μg/mL)
④↑ apoptosis ratep < 0.05 (100, 200, 400 μg/mL)
p < 0.05 (100 μg/mL), p < 0.01 (200, 400 μg/mL)
p < 0.01 (200, 400 μg/mL)
p < 0.01 (200, 400 μg/mL)
Zhang et al. (2020)A549 human lung cancer cell lineNegative control: No drugs①↑ A549 cell proliferation inhibition rate____p < 0.01
Positive drug: DDP, 0.5, 1, 5, 4, 6 μg/mL②A549 cell growth curve②NR
Aconitine group: 300, 600, 900, 1200, 1500 μg/mL (24,48,72 h)
Zou et al. (2021)Human osteosarcoma 143B cellsNegative control: No drugs①↓ cell viability⑴↑ caspase-3, ↑caspase-9p < 0.05
Aconitine group: 3.125, 6.25, 12.5, 25.00, 50.00 μg/mL (12,24,36 h)②↑ ROS positive ratep < 0.05 (3 μmol/L)
③↑ Gray scale ratio (p-JNK/β- actin)p < 0.05 (3 μmol/L)
④↑ apoptosis ratep < 0.05 (3 μmol/L)
⑤caspase mediated apoptosis⑤NR
p < 0.05 (3 μmol/L)
Prostate cancer cell DU145Negative control: No drugs①↓ cell proliferation and survival rate⑴↑ Bax, ↓ Bcl-2, ↓ p-JAK2, → JAK2, → p-STAT3, → STAT3 protein levelp < 0.05 (10,20 μg/mL)
Aconitine group: 5, 10, 20 μg/mL (48 h)②↓ number of cell invasionp = 0.000 < 0.05, t = 13.702
③↑ apoptosis ratep = 0.000 < 0.05, t = 29.336
p < 0.05 (Bax, Bcl-2), p < 0.05 (p-JAK2, p-STAT3), p > 0.05 (JAK2, STAT3)
Luan et al. (2022)MCF-7, MCF-7/ADR, NIH3T3 cell linePositive drug: DOX, etoposide, 0.2 mL①↑ anti-increment activity____p < 0.05
Aconitine group: 5, 10, 15 μM (48 h)②↑ G0/G1 phase, ↓ S phase②NR

Characteristics of included documents (Cell experiment).

Note, NR, not report; ↑, Upregulated expression, rising and increasing; ↓, Downregulated expression, decreased; →, Unchanged; DDP, cisplatin; 5-Fu, 5-Fluorouracil; DOX, doxorubicin; SDH, succinate dehydrogenase; ΔΨm, Mitochondrial membrane potential; p38MAPK, P38 mitogen activated protein kinase; TNF-R1, tumor necrosis factor-R1; Bax, Bcl-2-associated X protein; Bcl-2, B cell lymphoma 2; Cyt C, Cytochrome C; C/EBPα, regulatory transcription factors; EGF, epidermal growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; OSM, oncostatin-M; LDH, lactate dehydrogenase; Beclin1, Autophagy effector protein 1; MMP, matrix metalloproteinase; PGE2, Prostaglandin e2; IRF1, Interferon regulatory factor 1; Erβ, estrogen receptor β; VEGF, vascular endothelial growth factor A; HiF-α, hypoxia-inducible factor; PHd2, prolyl hydroxylase domain-containing protein 2; aTM, aTM, serine/threonine kinase; p-, phosphorylated; apaf-1, apoptotic peptidase activating factor 1; ParP, poly (adP-ribose) polymerase; PARP, poly (ADP-ribose) polymerase; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone; ROS, reactive oxygen species; COX IV, cytochrome oxidase subunit IV; E-Cadherin, Epithelial cadherin; PCNA, proliferating cell nuclear antigen; MRP2, multi-drug resistance protein 2; BCRP, breast cancer resistance protein; NKp46, NK, cell protein 46.

3.3 Included in literature quality evaluation

The CAMARADES evaluation form was utilized to assess the quality of the literature included in the 37 preclinical trials, as presented in Table 4. The studies were evaluated on a scale of 4-7, with an average score of 5.32. Among these studies, 4 (Zhao et al., 2014; Zhang et al., 2017; Wu et al., 2018; ); 10 (Zeng et al., 2007; Rao and Peng, 2010; Liu, 2013; ; Ma, 2017; Qi et al., 2018b; ; Wang, 2020; Wang et al., 2020; Luan et al., 2022) studies received 6 points; 18 (Xu et al., 2008; Zhu, 2008; ; Zhang and Wu, 2011; ; ; ; ; ; Ma and Yu, 2018; Xiong et al., 2018; Zhang et al., 2018; Shao et al., 2019; Zhou et al., 2019; Ru et al., 2020; Zhang et al., 2020; Zou et al., 2021; ) studies received 5 points; 5 (Tang and Sun, 1986; Yang et al., 2005; Ren and Zeng, 2008; Wuliji et al., 2008; ) studies received 4 scores. It is worth noting that all of these studies went through the peer review process before publication. While all studies were randomized, 11 of them (Tang and Sun, 1986; Yang et al., 2005; Zeng et al., 2007; Ren and Zeng, 2008; Wuliji et al., 2008; Rao and Peng, 2010; ; Zhang et al., 2017; Wu et al., 2018; ; Wang, 2020) failed to provide an accurate description of their grouping method, and 3 (Tang and Sun, 1986; Yang et al., 2005; Ren and Zeng, 2008) studies did not mention temperature control. Additionally, none of the studies mentioned implementing model-blinded or outcome-blinded methods. 9 (Zeng et al., 2007; Ren and Zeng, 2008; Rao and Peng, 2010; Zhao et al., 2014; Zhang et al., 2017; Wu et al., 2018; ; ; Wang, 2020) studies were found to mention lethal mode or anesthetic use. All of these studies utilized appropriate animal or cellular models and calculated the necessary data. 12 (Tang and Sun, 1986; Yang et al., 2005; Zeng et al., 2007; Rao and Peng, 2010; Liu, 2013; Zhao et al., 2014; Ma, 2017; Zhang et al., 2017; Wu et al., 2018; ; ; Wang, 2020) studies mentioned animal welfare regulations, and only 6 (; Zhang et al., 2017; Qi et al., 2018b; Wu et al., 2018; Wang et al., 2020; Luan et al., 2022) studies included a statement regarding potential conflicts of interest.

TABLE 4

Study (year)12345678910Total
Tang and Sun (1986)UKNRNRNRNR+++NR+4
Yang et al. (2005)UKNRNRNRNR+++NR+4
Zeng et al. (2007)UK+NRNR++++NR+6
Ren and Zeng (2008)UKNRNRNR+++NRNR+4
Wu et al. (2018)UK+NRNRNR++NRNR+4
Xu et al. (2008)++NRNRNR++NRNR+5
Zhu (2008)++NRNRNR++NRNR+5
Rao and Peng (2010)UK+NRNR++++NR+6
Zhang and Wu (2011)++NRNRNR++NRNR+5
++NRNRNR++NRNR+5
Liu (2013)++NRNRNR+++NR+6
++NRNRNR++NRNR+5
UK+NRNRNR++NRNR+4
Zhao et al. (2014)++NRNR++++NR+7
++NRNRNR++NRNR+5
++NRNRNR++NRNR+5
++NRNRNR++NR++6
Qi et al. (2018)UK+NRNR++++++7
++NRNRNR++NRNR+5
Ma (2017)++NRNRNR+++NR+6
Qi et al. (2018)++NRNRNR++NR++6
Wu et al. (2018)UK+NRNR++++++7
Ma and Yu (2018)++NRNRNR++NRNR+5
Xiong et al. (2018)++NRNRNR++NRNR+5
Zhang et al. (2018)++NRNRNR++NRNR+5
UK+NRNR++++NR+6
Shao et al. (2019)++NRNRNR++NRNR+5
Zhou et al. (2019)++NRNRNR++NRNR+5
++NRNR++++NR+7
Ru et al. (2020)++NRNRNR++NRNR+5
Wang et al. (2020)++NRNRNR++NR++6
Wang (2020)UK+NRNR++++NR+6
Zhang et al. (2020)++NRNRNR++NRNR+5
++NRNRNR++NRNR+5
Zou et al. (2021)++NRNRNR++NRNR+5
++NRNRNR++NRNR+5
Luan et al. (2022)++NRNRNR++NR++6

Quality assessment of the experiments included in the studies.

Note, 1, Random grouping; 2, A statement describing temperature control; 3, Model blind method; 4, Results were evaluated by blind method; 5, The use of anesthetics has no obvious intrinsic myocardial protection or neuroprotective effect; 6, Appropriate animal or cell models; 7, Calculation of sample size; 8, Follow animal welfare regulations; 9, Declare any potential conflict of interest; 10, The paper was published after peer review; UK, unknow, only the random grouping is explained, and the random grouping method is not specified; NR, not report.

3.4 Meta analysis results

3.4.1 Tumor weight

Seven studies were analyzed to compare the change in tumor weight between the control and experimental groups. Heterogeneity was observed between the (Tau2 = 0.28, Chi2 = 73.07, df = 6, I2 = 92%, p < 0.00001), so a random-effects model was utilized. The findings indicated a significant difference in tumor weight between the treatment and control groups (Z = 5.81, p < 0.00001) with a 95% confidence interval of [MD = −1.28, 95% CI (−1.72, −0.85)]. The results were shown in Figure 4.

FIGURE 4

3.4.2 Proliferation number of tumor cells

Cell proliferation is a crucial aspect of an organism’s life, occurring through cell division. Protozoans generate new individuals through cell division, while multicellular organisms produce new cells to replace aging or dying cells within the body (). Cancer cells, on the other hand, possess three significant traits: infinite proliferation (), the ability to transform and metastasize, and the capacity to destroy normal cellular tissues. Therefore, the value-added number of tumor cells is one of the important indicators for the evaluation of antitumor efficacy ().

Two studies were analyzed to compare changes in cell proliferation numbers between control and experimental groups. Heterogeneity was observed between trials (Tau2 = 0.06, Chi2 = 166.34, df = 1, I2 = 99%, p < 0.00001), requiring the use of a random effects model. The results indicated a significant difference between the control and experimental groups (Z = 3.84, p = 0.0001) with a 95% confidence interval of [MD = −0.64, 95% CI (−0.97, −0.31)]. This indicated that aconitine could reduce the number of tumor cell proliferation in mice. The results were shown in Figure 5.

FIGURE 5

3.4.3 Thymus index

The thymic index, also referred to as the thymic secretion index, is primarily based on the level of lymphocyte multiplication and can serve as a means to gauge immune intensity ().

A total of two studies were included to compare the change in thymic index between the control and experimental groups. Due to heterogeneity between trials (Chi2 = 10.56, df = 1, I2 = 91%, p = 0.001), a random-effects model was utilized. The results showed a statistically significant difference in thymic index between the treatment and control groups (Z = 39.30, p < 0.00001), with a 95% confidence interval of [MD = −0.61, 95% CI (−0.64, −0.58)]. The results of this study showed that aconitine could reduce the thymic index in mice. The results were shown in Figure 6.

FIGURE 6

3.4.4 Number of metastatic lesions

Metastatic lesions refer to tumor cells that spread from the primary site through lymphatic vessels, blood vessels, or other pathways to other areas of the body where they continue to grow, forming the same type of tumor as the primary site. This process is known as metastasis, and the resulting tumors are called metastases or metastatic cancer (Suhail et al., 2019). The evaluation of the number of metastatic lesions is frequently used in antitumor studies because of the susceptibility of tumor cells to metastasize.

A total of two studies were included to compare the changes in the number of metastatic lesions between the control and experimental groups, and there was heterogeneity between the trials (Tau2 = 79.22, Chi2 = 56.40, df = 1, I2 = 98%, p < 0.00001), so a random-effects model was used. T The results indicated that there was no significant difference in the number of metastatic lesions between the treatment and control groups (Z = 1.33, p = 0.18). Therefore, it cannot be concluded that aconitine has the ability to reduce the number of metastatic lesions in mice. The results were shown in Figure 7.

FIGURE 7

3.4.5 Tumor cell apoptosis rate

Apoptosis is a genetically controlled process of autonomous and orderly cell death that helps maintain the stability of the internal environment (). In contrast, cancer cells can evade apoptosis and grow uncontrollably. As a result, the effectiveness of drugs in treating tumors is frequently evaluated by measuring the apoptosis rate of cancer cells.

A total of seven studies were included to compare apoptosis rates between control and experimental groups, and there was heterogeneity between trials (Tau2 = 382.07, Chi2 = 40,694.89, df = 6, I2 = 100%, p < 0.00001), so a random-effects model was used. The results indicated a significant difference in apoptosis rate between the treatment and control groups (Z = 4.14, p < 0.0001) with a 95% confidence interval of [MD = 30.62,95% CI (16.13, 45.11)]. The results of this study showed that aconitine could increase the apoptosis rate of tumor cells. The results were shown in Figure 8.

FIGURE 8

3.4.6 OD value of cell proliferation

The OD value, or optical density value, is a widely used indicator in cellular experiments that measures the amount of light absorbed by the assay. As the number of bacteria in the medium increases, so does the absorbance value within a certain range. Therefore, the OD value is often utilized as a test indicator to assess the proliferation of cells following administration.

A total of seven studies were included to compare the cell proliferation OD between control and experimental groups, with heterogeneity between trials (Tau2 = 0.02, Chi2 = 3062.23, df = 6, I2 = 100%, p < 0.00001), so a random effects model was used. The results showed a statistically significant difference between the treatment and control groups (Z = 11.72, p < 0.00001) with a 95% confidence interval of [MD = −0.63, 95% CI (−0.74, −0.53)]. The results of this study showed a decrease in cell proliferation OD. The results were shown in Figure 9.

FIGURE 9

3.4.7 Bcl-2 expression level

Bcl-2, also known as the B cell lymphoma/leukemia-2, is an oncogene that plays a crucial role in inhibiting cell apoptosis (). As a major target molecule in the study of molecular mechanisms of apoptosis (), it has garnered significant attention in antitumor research.

A total of three studies were included to compare the anti-cycloguanine peptides between the control and experimental groups. There was some heterogeneity between the trials (Tau2 = 0.00, Chi2 = 6.50, df = 2, I2 = 69%, p = 0.04), so a random effects model was used. The results revealed a statistically significant difference between the treatment and control groups (Z = 22.33, p < 0.00001) with a 95% confidence interval of [MD = −0.66, 95% CI (−0.71, −0.60)]. The results of this study showed that aconitine reduced the expression of Bcl-2. The results were shown in Figure 10.

FIGURE 10

Overall, aconitine demonstrated a more significant anti-tumor effect by reducing tumor weight, inhibiting proliferation and migration of tumor cells, promoting apoptosis, and controlling gene/protein expression of cancer cells, including Bcl-2, Bax, Caspase-3, Caspase-8, Cleaved Caspase-9, and others.

When the value of I2 exceeds 50%, it is necessary to conduct a subgroup analysis to investigate the underlying cause of the high heterogeneity. However, the meta-analysis indexes mentioned above have insufficient literature included, such as cell proliferation, thymus index, and number of metastatic lesions indexes. As a result, these indexes may not provide sufficient evidence to support the effectiveness of aconitine against tumors. After reviewing the literature, it became evident that the lack of inclusion of certain studies was because they did not consider the co-administration of aconitine during the screening process.

For instance, one research of Li et al. on the synergistic induction of apoptosis in cervical cancer through the use of quercetin and aconitine, where HeLa cell proliferation was utilized as an outcome indicator (Li et al., 2018); In their study on anti-breast cancer MDA-MB-231BO cells, Guo et al. utilized a combination of osteopontin and aconitine to effectively inhibit cancer cell invasion (); Similarly, Yao et al. found success in treating hepatocellular carcinoma by combining aconitine with Crude Monkshood Polysaccharide, as evidenced by positive experimental outcome indicators such as thymic index (Yao et al., 2021).

The above experiments showed that the meta-analysis indexes used in this study were able to reflect the anti-tumor efficacy of aconitine to some extent. However, due to the absence of quantitative data analysis for integrated and multidimensional purposes in many studies, there is a need for larger sample sizes in in vivo or in vitro experiments to fully understand the multifaceted antitumor effects of aconitine. This is necessary for a rational and proper assessment of its antitumor efficacy.

4 Discussion

4.1 Limitation

When conducting a systematic and comprehensive meta-analysis to evaluate the antitumor efficacy of aconitine, it is important to acknowledge certain limitations. First of all, this study only included literature in Chinese and English, which may introduce a selection bias as there may be relevant studies published in other languages that were not considered. Secondly, the various articles investigating the action of aconitine on tumor cells utilize different methods of administration, control groups, doses, and durations of action. As a result, discrepancies arise in the assays and the results become incomparable. Thirdly, a quality assessment score below 5 indicates a low quality of the methods utilized in the study. Furthermore, many of the studies lacked proper reporting and had flaws in their random assignment and blinding of results. These issues make it challenging to assess the studies’ quality and the trustworthiness of the data.

In addition, the majority of the articles lacked raw data and only included analytical plots and corresponding p values for comparisons between control groups. This limited our ability to refine the data and analyze the anti-tumor efficacy of aconitine using multiple indicators through meta-analysis. Therefore, it is important to assess and interpret the antitumor effects of aconitine at various levels with rationality. In order to conduct a thorough follow-up protocol on the antitumor efficacy study of aconitine, researchers should consider using a similar or equivalent dose range, frequency, duration of action, and control group during the experimental implementation phase. This will enable them to analyze and study the data more accurately in subsequent in-depth studies.

4.2 Implication

The antitumor effects of Aconitine are a complex process that involves multiple factors that have yet to be fully explained. Currently, the main mechanisms of Aconitine anti-tumor properties have been reported in the literature, with a primary focus on the expression of Bax, Bcl-2, Caspase-3, and other proteins, reactive oxygen species damage and the triggering of apoptosis and autophagy in tumor cells.

The literature included in this study commonly used animal indicators such as tumor weight, tumor volume, and thymus index. Cellular experiments frequently measured cell proliferation inhibition rate, apoptosis rate, and cell count at different time periods. In mechanism studies, apoptosis-related targets such as Bax, cyto. C, and caspase-3/9 expression were upregulated, while Bcl-2, pro-caspase 9, MMP2/9, and VEGF expression were downregulated. Based on the changes observed in the expression of these targets, we have formulated a hypothesis that suggests the primary signaling pathway for aconitine anti-tumor effects is NF-κB, and the primary acting immune organ is the thymus. The relevant mechanisms were shown in Figure 11A. The mechanisms through which aconitine induces apoptosis in tumor cells, as discussed earlier, offer numerous opportunities for future researchers to delve deeper into the properties of aconitine alkaloids. Additionally, these tests are acknowledged as essential in the development and clinical application of proprietary Chinese medicines that contain aconite medicinal plants.

FIGURE 11

4.3 Thymus immune organs and T lymphocytes

The thymus, a central immune organ, is situated behind the sternum and in close proximity to the heart. It is divided into two lobes, left and right, and primarily composed of the cortex and the medulla (Rodewald, 2008; ). The cortex is mainly composed of larger, immature T lymphocytes, while the medulla contains smaller, less abundant mature T lymphocytes. Due to its significance in the immune system, the thymus is frequently studied in antitumor animal model research.

Cytotoxic T lymphocytes (CTL) are a specialized type of T cell that secretes various immune-related cytokines. Along with natural killer cells, they form a crucial line of defense for the body’s antiviral and antitumor immunity (Rascio et al., 2021). CD8+ T cells and CD4+ T cells are both types of CTL and are believed to have a dominant role in producing an effective anti-tumor response ().

Cytotoxic T lymphocytes (CTL) are a specialized type of T cell that secretes various immune-related cytokines. Along with natural killer cells, they form a crucial line of defense for the body’s antiviral and antitumor immunity (Rascio et al., 2021). CD8+ T cells and CD4+ T cells are both types of CTL and are believed to have a dominant role in producing an effective anti-tumor response ().

CD8+ T cells are known to have the ability to directly eliminate tumor cells, making them the preferred immune cells for targeting tumors (). However, in order to achieve effective anti-tumor immunity, the complementary CD4+ T cells are also necessary ().

CD8+ T cells are known to have the ability to directly eliminate tumor cells, making them the preferred immune cells for targeting tumors (), However, in order to achieve effective anti-tumor immunity, the complementary CD4+ T cells are also necessary (). Research has shown that aconitine has multiple effects on cells. It induces apoptosis in tumor cells and activates voltage-dependent Na+ channels in the thymus, which leads to the binding of Ca2+ to downstream molecules and a decrease in free Ca2+ in cells. Additionally, aconitine promotes DP toward SPCD4 and promotes thymic T cell development, maturation, and efflux (Lo et al., 2012). It also increases the percentage of T cells in the spleen and mesenteric lymph nodes, as well as the production of IFN-γ in the spleen and draining lymph nodes, resulting in anti-tumor effects (Zhang, 2021). When aconitine reaches a certain dosage, it can decrease the percentage of Treg obtained by the organism. However, at low doses, not only does it not reduce the percentage of Treg (), but it can even encourage the differentiation of peripheral blood T cells into Treg (). This is done to suppress the function of CD8+ T cells, which ultimately leads to a lower thymic index. Immune cells produce cytokines TNF-α, IL-1β, and IFN-γ, which play crucial roles in immunomodulation and intercellular communication within the immune system. Additionally, these cytokines are essential for the differentiation of memory T cells (). During tumor development, the body exerts its immune function mainly by regulating the secretion of cytokines (). Aconitine alkaloids have been shown to promote the secretion of cytokines like TNF-α, IL-1β, and IFN-γ in cancer model mice, thereby enhancing the immune function of the body (Wu et al., 2021).

4.4 Regulatory genes related to autophagy and apoptosis

Autophagy is a cellular process where cells engulf their own cytoplasmic proteins or organelles, encapsulate them into vesicles, and fuse with lysosomes to form autolysosomes. This process allows for the degradation of the encapsulated contents, which satisfies the metabolic needs of the cell and facilitates the renewal of specific organelles. Autophagy is closely linked to cell growth, apoptosis, and internal environmental homeostasis () () (Maiuri et al., 2007). Autophagy is a self-degrading system that is conserved across species and plays a crucial role in maintaining cellular homeostasis during periods of stress (Onorati et al., 2018). However, when autophagy becomes dysregulated, it can have significant implications for human health and disease. Research suggests that inhibiting autophagy may be a promising therapy for advanced cancers. It is important to note that autophagy is not a singular process, but rather requires interaction with various signaling pathways. Furthermore, it is closely linked to apoptosis (; Li et al., 2017) (Maheswari et al., 2018). Bcl-2 is the anti-apoptotic gene that is most strongly linked to apoptosis, while Bax is a pro-apoptotic gene that opposes Bcl-2 (; ). During the apoptosis signaling process, the Bcl-2 and Bax genes can regulate the activity of the Caspase-3 gene, which in turn controls the apoptotic process via the mitochondrial pathway (Yaidikar and Thakur, 2015). Caspase-3 plays a crucial role in the apoptotic process as the major terminal shear enzyme and the primary executor. Upon initiation of apoptosis, Caspase-3 protein is activated, and its activating protein, Active Caspase-3 protein, can specifically shear DNA. This prompts cytoplasmic coagulation and nucleic acid activation, ultimately leading to apoptosis (). In contrast, the results of several papers included in this study, the upregulation of Bax expression and the downregulation of Bcl-2 expression demonstrate that aconitine can promote the expression of apoptotic genes and cause excessive autophagy in cancer cells, which leads to apoptosis. In contrast to other papers examined in this study, the findings indicated that aconitine could promote the expression of apoptotic genes/proteins and excessive autophagy in cancer cells by upregulating Bax expression and downregulating Bcl-2 expression, ultimately leading to apoptosis.

4.5 NF-κB signal pathway

Generally, the Bax and Bcl-2 genes work together to maintain a balanced state and facilitate a normal apoptotic process (Siddiqui et al., 2015; Warren et al., 2019). The anti-apoptotic effect of cells is initiated through the activation of a positive cascade of amplified signaling pathways, which are primarily controlled by NF-κB mediated by different survival factors via receptor kinases (Sonenshein, 1997; ).

Since incorporation of literature demonstrates that aconitine could upregulate Bax and downregulates Bcl-2 expression. Additionally, studies by Ren and Jia demonstrate that aconitine can downregulate the expression of NF-κB pathway (Ren and Zeng, 2008; ). Based on this information, it is reasonable to speculate that aconitine achieves its antitumor efficacy through NF-κB signaling pathways. A possible mechanism of aconitine action on the NF-κB signaling pathway were illustrated in Figure 11B.

Under non-activating conditions, NF-κB exists in an inactive form within the cell plasma, and upon extracellular stimulation (e.g., viral or bacterial infection, UV irradiation, etc.), the NF-κB signaling pathway begins to activate (Wu and Kral, 2005). This activation occurs when extracellular signaling factors bind to receptors on the cell membrane, initiating a cascade of downstream responses. The receptor protein receives stimulation and activates I κB kinase (IKK) first (Oeckinghaus and Ghosh, 2009). Intracellular NF-κB-I κB complex is phosphorylated by IKK, which allows for the modification and degradation of I κB, resulting in the release of NF-κB dimers (). These free NF-κB dimers enter the nucleus to bind to genes containing NF-κB binding sites and initiate the transcriptional process (). Additionally, NF-κB activates the expression of the I κBα gene, and newly synthesized I κBα re-inhibits NF-κB activity (; Smale, 2012). NF-κB plays a crucial role in regulating cellular responses due to its ability to quickly activate as a master transcription factor without the need for new protein synthesis. It acts as the first responder to harmful stimuli within cells. Several studies (; ; Vasudevan et al., 2004; ) have shown that NF-κB inhibits apoptosis through three primary pathways: ① NF-κB plays a role in both self and other cell apoptosis through the regulation of cytokines; ②NF-κB inhibits apoptosis by inducing or upregulating anti-apoptotic genes; and ③NF-κB inhibits apoptosis by inducing TRAF and IAP.

The NF-κB pathway has a number of known activators, including TNF-α (Liu et al., 2021), interleukin cytokines (), chemokines (Zhao et al., 2021), and colony-stimulating factors (Schreck and Baeuerle, 1990). In addition, some anti-inflammatory molecules such as zinc finger protein (Ye et al., 2019; Zhang et al., 2021), HO-1 (; Saha et al., 2020) and molecules related to apoptosis (TRAF-1, IAP1/IAP2, TRAF1/TRAF2) are also regulated by NF-κB (Zusso et al., 2019; ).

The NF-κB pathway’s anti-apoptotic mechanism involves inhibiting the activation of caspase-8, which in turn inhibits downstream caspase-3. This inhibition is achieved by regulating the expression of TRAF1, TRAF2, c-IAP1, and c-IAP2. Inclusion studies indicate that aconitine is likely to promote the expression of the Bax gene and suppress that of the Bcl-2 gene by regulating the NF-κB signaling pathway. Additionally, aconitine regulates the expression of cell cycle proteins, thereby inhibiting tumor cell proliferation and inducing apoptosis. The anti-apoptotic mechanism of NF-κB is to inhibit the activation of caspase-8 (; Schneider et al., 2017) and thus downstream caspase-3 (Luo et al., 2019; Sangaran et al., 2021; Sun et al., 2021) by regulating the expression of TRAF1, TRAF2, c-IAP1, and c-IAP2. Inclusion studies suggested that aconitine was likely to promote the expression of the Bax and suppress that of the Bcl-2 by regulating the NF-κB signaling pathway. Additionally, aconitine could regulate the expression of cell cycle proteins, thereby inhibiting tumor cell proliferation and inducing apoptosis.

5 Conclusion

Although aconitine is highly toxic, it has a remarkable anti-tumor effect. Its mechanism of action is complex, but it inhibits tumor cell proliferation and induces apoptosis. Aconitine activates voltage-dependent Na+ channels in the thymus, promoting thymic T cell development, while also inhibiting Bcl-2 gene expression and activating the downstream gene Caspase-3 to promote tumor cell apoptosis through the regulation of the NF-κB signaling pathway.

Studies have shown that aconitine is highly toxic, with lethal doses (LD50) of 0.2702 ± 0.002 mg/kg in mice, respectively (Zhou et al., 1984). Although aconitine is highly toxic, it has a remarkable anti-tumor effect. It inhibits tumor cell proliferation and induces apoptosis with a complex mechanism, which may inhibit tumor cells by activating voltage-dependent Na+ channels in the thymus and promoting thymic T cell development on the one hand. on the other hand, it inhibits Bcl-2 expression and activates the downstream Caspase-3 to promote tumor cell apoptosis by regulating the NF-κB signaling pathway. However, the precise mechanism of aconitine remains unexplored in both preclinical and clinical trials, whether in vivo or in vitro. At the same time, the challenge of regulating the dosage of aconitine in isolation during clinical trials has led to its frequent use as part of a combination drug in multidrug resistance trials for certain drug-resistant medications. But there are limited in vitro and in vivo preclinical and clinical studies on this subject, making it a key area of investigation for advancing the clinical application of aconitine.

Statements

Data availability statement

The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding author.

Author contributions

GX, conceptualization, data curation and writing-original draft. GX and NX, data extraction and interpretation. SW, conceptualization and writing-review and editing; YZ, writing-review and editing and supervision.

Funding

This study was supported by the National Natural Science Foundation of China (82130113).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AhrendsT.SpanjaardA.PilzeckerB.BąbałaN.BovensA.XiaoY.et al (2017). CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity47 (5), 848e5. 10.1016/j.immuni.2017.10.009

  • 2

    AlbanoF.VecchioE.RennaM.IaccinoE.MimmiS.CaiazzaC.et al (2019). Insights into thymus development and viral thymic infections. Viruses11 (9), 836. 10.3390/v11090836

  • 3

    AliS.MannD. A. (2004). Signal transduction via the NF-kappaB pathway: A targeted treatment modality for infection, inflammation and repair. Cell. biochem. Funct.22 (2), 6779. 10.1002/cbf.1082

  • 4

    BaeuerleP. A.HenkelT. (1994). Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol.12, 141179. 10.1146/annurev.iy.12.040194.001041

  • 5

    BaskarR.LeeK. A.YeoR.YeohK. W. (2012). Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci.9 (3), 193199. 10.7150/ijms.3635

  • 6

    BruckheimerE. M.ChoS. H.SarkissM.HerrmannJ.McDonnellT. J. (1998). The Bcl-2 gene family and apoptosis. Adv. Biochem. Eng. Biotechnol.62, 75105. 10.1007/BFb0102306

  • 7

    CaiG. Q. (2022). Effect of aconitine on proliferation, invasion and apoptosis of prostate cancer cells and its mechanism. Chin. J. Gerontology42 (09), 22632266.

  • 8

    Castañeda-DelgadoJ. E.Frausto-LujanI.González-CurielI.Montoya-RosalesA.SerranoC. J.Torres-JuarezF.et al (2017). Differences in cytokine production during aging and its relationship with antimicrobial peptides production. Immunol. Investig.46 (1), 4858. 10.1080/08820139.2016.1212873

  • 9

    ChanY. T.WangN.FengY. (2021). The toxicology and detoxification of aconitum: Traditional and modern views. Chin. Med.16 (1), 61. 10.1186/s13020-021-00472-9

  • 10

    ChenH.TianB.FangX.BaiJ.MaQ.ZhangY.et al (2021). Injectable erythrocyte gel loaded with bulleyaconitine A for the treatment of rheumatoid arthritis. ACS Biomater. Sci. Eng.7 (12), 57065716. 10.1021/acsbiomaterials.1c01175

  • 11

    ChengC. (2019). Intervention of aconitine on Treg in gastric cancer-bearing mice by regulating PGE2/COX2 pathway. Hefei: Anhui University of Chinese Medicine, 65.

  • 12

    ChengC.ZengY. L.WangJ.WuY.ZangL. B. (2020). Effect observation of aconitine on the expression of PGE2 in peripheral blood mononuclear cells of normal 615 mice and its regulation on Treg. J. Liaoning Univ. Traditional Chin. Med.22 (04), 4246.

  • 13

    ChudeC. I.AmaravadiR. K. (2017). Targeting autophagy in cancer: Update on clinical trials and novel inhibitors. Int. J. Mol. Sci.18 (6). 10.3390/ijms18061279

  • 14

    ClarkeP.DebiasiR. L.MeintzerS. M.RobinsonB. A.TylerK. L. (2005). Inhibition of NF-kappa B activity and cFLIP expression contribute to viral-induced apoptosis. Apoptosis10 (3), 513524. 10.1007/s10495-005-1881-4

  • 15

    CoryS.AdamsJ. M. (2005). Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell.8 (1), 56. 10.1016/j.ccr.2005.06.012

  • 16

    DingY.LuY. W. (2019). [Comprehensive nursing intervention helps improve medication compliance of prostate cancer patients undergoing endocrine therapy]. Zhonghua Nan Ke Xue25 (5), 434436.

  • 17

    DingY. X. (2014). Experimental research on aconite alkaloids in inhibiting human gastric cell line SGC-7901 and the synergistic interaction between aconite alkaloids and chemotherapeutic agents. Nanjing: Nanjing University Of Chinese Medicine, 59.

  • 18

    DingY. X.ZouX.WuJ.GeH. L.HuS. Y. (2013). Effects of aconite alkaloids on apoptosis and cell cycle of human gastric cancer cell line SGC-7901. Mod. Traditional Chin. Med. Materia Medica-World Sci. Technol.15 (05), 915919.

  • 19

    DohrmanA.KataokaT.CueninS.RussellJ. Q.TschoppJ.BuddR. C. (2005). Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-kappa B activation. J. Immunol.174 (9), 52705278. 10.4049/jimmunol.174.9.5270

  • 20

    DolcetX.LlobetD.PallaresJ.Matias-GuiuX. (2005). NF-kB in development and progression of human cancer. Virchows Arch.446 (5), 475482. 10.1007/s00428-005-1264-9

  • 21

    DuJ.LuX.LongZ.ZhangZ.ZhuX.YangY.et al (2013). In vitro and in vivo anticancer activity of aconitine on melanoma cell line B16. Molecules18 (1), 757767. 10.3390/molecules18010757

  • 22

    EbrahimA. S.SabbaghH.LiddaneA.RaufiA.KandouzM.Al-KatibA. (2016). Hematologic malignancies: Newer strategies to counter the BCL-2 protein. J. Cancer Res. Clin. Oncol.142 (9), 20132022. 10.1007/s00432-016-2144-1

  • 23

    EfferthT.OeschF. (2021). The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. Med. Res. Rev.41 (6), 30233061. 10.1002/med.21842

  • 24

    ElmoreS. (2007). Apoptosis: A review of programmed cell death. Toxicol. Pathol.35 (4), 495516. 10.1080/01926230701320337

  • 25

    FanY.JiangY.LiuJ.KangY.LiR.WangJ. (2016). The anti-tumor activity and mechanism of alkaloids from Aconitum szechenyianum Gay. Bioorg. Med. Chem. Lett.26 (2), 380387. 10.1016/j.bmcl.2015.12.006

  • 26

    FarhoodB.NajafiM.MortezaeeK. (2019). CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol.234 (6), 85098521. 10.1002/jcp.27782

  • 27

    FerroF.ServaisS.BessonP.RogerS.DumasJ. F.BrissonL. (2020). Autophagy and mitophagy in cancer metabolic remodelling. Semin. Cell. Dev. Biol.98, 129138. 10.1016/j.semcdb.2019.05.029

  • 28

    GaoX.HuJ.ZhangX.ZuoY.WangY.ZhuS. (2020). Research progress of aconitine toxicity and forensic analysis of aconitine poisoning. Forensic Sci. Res.5 (1), 2531. 10.1080/20961790.2018.1452346

  • 29

    GaoY.FanH.NieA.YangK.XingH.GaoZ.et al (2022). Aconitine: A review of its pharmacokinetics, pharmacology, toxicology and detoxification. J. Ethnopharmacol.293, 115270. 10.1016/j.jep.2022.115270

  • 30

    GarmanchoukL. V.PyaskovskayaO. N.YanishY. V.ShlyakhovenkoV. A.DasyukevichO. I.SolyanikG. I. (2005). Influence of aconitine-containing herbal extract BC1 on proliferative and electrokinetic characteristics of endothelial cells. Exp. Oncol.27 (4), 262266.

  • 31

    GilmoreT.GapuzanM. E.KalaitzidisD.StarczynowskiD. (2002). Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett.181 (1), 19. 10.1016/s0304-3835(01)00795-9

  • 32

    GlasziouP.VandenbrouckeJ. P.ChalmersI. (2004). Assessing the quality of research. BMJ328 (7430), 3941. 10.1136/bmj.328.7430.39

  • 33

    GlickD.BarthS.MacleodK. F. (2010). Autophagy: Cellular and molecular mechanisms. J. Pathol.221 (1), 312. 10.1002/path.2697

  • 34

    GuanX.ChenS.ZhaoY. (2018). The role of RhoC in malignant tumor invasion, metastasis and targeted therapy. Histol. Histopathol.33 (3), 255260. 10.14670/HH-11-915

  • 35

    GuanX.YangT. H.ZhangA. L.SuM. C.ZhaoR. L.ZhangC. R.et al (2015). Mesaconitine extracted from radix aconiti lateralis preparata aconite inhibited proliferation and induced apoptosis of human erythroleukemia (K562) cell line. J. Beijing Univ. Traditional Chin. Med.38 (07), 467472+2.

  • 36

    GuanX.YangT. H.ZhangC. R.FengS. (2017). Induction effect of mesaconitine on apoptosis of K562 and K562/DNR cells and related mechanism. Acta Med. Univ. Sci. Technol. Huazhong46 (03), 281284.

  • 37

    GuoB. F.LiuS.YeY. Y.HanX. H. (2011). [Inhibitory effects of osthole, psoralen and aconitine on invasive activities of breast cancer MDA-MB-231BO cell line and the mechanisms]. Zhong Xi Yi Jie He Xue Bao9 (10), 11101117. 10.3736/jcim20111012

  • 38

    HäckerH.KarinM. (2006). Regulation and function of IKK and IKK-related kinases. Sci. STKE2006 (357), re13. 10.1126/stke.3572006re13

  • 39

    HaoW. Q. (2014). Study on the chemical constituents of the alkaloids from the root of aconitum flavum hand.-mazz and its anti-tumor activities. Yinchuan: Ningxia Medical University, 88.

  • 40

    HawsawiY. M.Al-ZahraniF.MavromatisC. H.BaghdadiM. A.SagguS.OyouniA. (2018). Stem cell applications for treatment of cancer and autoimmune diseases: Its promises, obstacles, and future perspectives. Technol. Cancer Res. Treat.17, 1533033818806910. 10.1177/1533033818806910

  • 41

    HeG.KarinM. (2011). NF-κB and STAT3 - key players in liver inflammation and cancer. Cell. Res.21 (1), 159168. 10.1038/cr.2010.183

  • 42

    JarrettA. M.LimaE.HormuthD. N.McKennaM. T.FengX.EkrutD. A.et al (2018). Mathematical models of tumor cell proliferation: A review of the literature. Expert Rev. Anticancer Ther.18 (12), 12711286. 10.1080/14737140.2018.1527689

  • 43

    JiB.XiaL.ZhouF.MaoG.XuL. (2016). Aconitine induces cell apoptosis in human pancreatic cancer via NF-κB signaling pathway. Eur. Rev. Med. Pharmacol. Sci.20 (23), 49554964.

  • 44

    JiX. M. (2021). The study of miR-144 suppressing cells proliferation and migration in colorectal cancer by targeting NRAS. Guangzhou: Southern Medical University, 112.

  • 45

    JiX.YangM.OrK. H.YimW. S.ZuoZ. (2019). Tissue accumulations of toxic aconitum alkaloids after short-term and long-term oral administrations of clinically used radix aconiti lateralis preparations in rats. Toxins (Basel)11 (6). 10.3390/toxins11060353

  • 46

    JiaM.ZhangH. (2011). Effect of ampelopsis japonica and aconite alone and their combination on proliferation and apoptosis of human gastric cancer cell SGC-7901. Mod. J. Integr. Traditional Chin. West. Med.20 (27), 33883390.

  • 47

    JiangH.ZhangY.ZhangY.WangX.MengX. (2022). An updated meta-analysis based on the preclinical evidence of mechanism of aconitine-induced cardiotoxicity. Front. Pharmacol.13, 900842. 10.3389/fphar.2022.900842

  • 48

    JinL.WangC.LiuJ.LiP.LiJ.CuiX.et al (2020). Pseudo-ginsengenin DQ ameliorated aconitine-induced arrhythmias by influencing Ca2+ and K+ currents in ventricular myocytes. RSC Adv.10 (43), 2599926005. 10.1039/d0ra01683g

  • 49

    KimH. N.ParkG. H.ParkS. B.KimJ. D.EoH. J.SonH. J.et al (2019). Sageretia thea inhibits inflammation through suppression of NF- κ B and MAPK and activation of Nrf2/HO-1 signaling pathways in RAW264.7 cells. Am. J. Chin. Med.47 (2), 385403. 10.1142/S0192415X19500198

  • 50

    KishtonR. J.SukumarM.RestifoN. P. (2017). Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell. Metab.26 (1), 94109. 10.1016/j.cmet.2017.06.016

  • 51

    KleinG.Vande WoudeW. G. (2008). Advances in cancer research: Centennial volume. Introduction. Adv. Cancer Res.100, vvii. 10.1016/S0065-230X(08)00008-0

  • 52

    KorsmeyerS. J.ShutterJ. R.VeisD. J.MerryD. E.OltvaiZ. N. (1993). Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol.4 (6), 327332.

  • 53

    Kotel'nikovV. M. (1989). [Predictive significance of parameters of tumor cell proliferation]. Eksp. Onkol.11 (5), 39.

  • 54

    KubatkaP.UramovaS.KelloM.KajoK.SamecM.JasekK.et al (2019). Anticancer activities of thymus vulgaris L. In experimental breast carcinoma in vivo and in vitro. Int. J. Mol. Sci.20 (7). 10.3390/ijms20071749

  • 55

    KüperC.BartelsH.BeckF. X.NeuhoferW. (2011). Cyclooxygenase-2-dependent phosphorylation of the pro-apoptotic protein Bad inhibits tonicity-induced apoptosis in renal medullary cells. Kidney Int.80 (9), 938945. 10.1038/ki.2011.199

  • 56

    Legrand-PoelsS.SchoonbroodtS.MatrouleJ. Y.PietteJ. (1998). Nf-kappa B: An important transcription factor in photobiology. J. Photochem Photobiol. B45 (1), 18. 10.1016/S1011-1344(98)00118-3

  • 57

    LiC. Y.ZhouZ.XuT.WangN. Y.TangC.TanX. Y.et al (2022). Aconitum pendulum and aconitum flavum: A narrative review on traditional uses, phytochemistry, bioactivities and processing methods. J. Ethnopharmacol.292, 115216. 10.1016/j.jep.2022.115216

  • 58

    LiM.XieX.ChenH.XiongQ.TongR.PengC.et al (2020). Aconitine induces cardiotoxicity through regulation of calcium signaling pathway in zebrafish embryos and in H9c2 cells. J. Appl. Toxicol.40 (6), 780793. 10.1002/jat.3943

  • 59

    LiS.YuL.ShiQ.LiuY.ZhangY.WangS.et al (2022). An insight into current advances on pharmacology, pharmacokinetics, toxicity and detoxification of aconitine. Biomed. Pharmacother.151, 113115. 10.1016/j.biopha.2022.113115

  • 60

    LiX. M.LiuJ.PanF. F.ShiD. D.WenZ. G.YangP. L. (2018). Quercetin and aconitine synergistically induces the human cervical carcinoma HeLa cell apoptosis via endoplasmic reticulum (ER) stress pathway. PLoS One13 (1), e0191062. 10.1371/journal.pone.0191062

  • 61

    LiY. J.LeiY. H.YaoN.WangC. R.HuN.YeW. C.et al (2017). Autophagy and multidrug resistance in cancer. Chin. J. Cancer36 (1), 52. 10.1186/s40880-017-0219-2

  • 62

    LinC.ClarkR.TuP.BosworthH. B.ZulligL. L. (2017). Breast cancer oral anti-cancer medication adherence: A systematic review of psychosocial motivators and barriers. Breast Cancer Res. Treat.165 (2), 247260. 10.1007/s10549-017-4317-2

  • 63

    LiuB.YanX.HouZ.ZhangL.ZhangD. (2021). Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-κB signaling path. Bioengineered12 (1), 27232733. 10.1080/21655979.2021.1937911

  • 64

    LiuY. (2013). Research on pharmacognosy & alkaloids & acute toxicity & anticancer activity of Kazakh medicine aconitum leucostomum worosch. Wulumuqi: Xinjiang Medical University, 62.

  • 65

    LoW.DonermeyerD. L.AllenP. M. (2012). A voltage-gated sodium channel is essential for the positive selection of CD4(+) T cells. Nat. Immunol.13 (9), 880887. 10.1038/ni.2379

  • 66

    LuanS.GaoY.LiangX.ZhangL.WuQ.HuY.et al (2022). Aconitine linoleate, a natural lipo-diterpenoid alkaloid, stimulates anti-proliferative activity reversing doxorubicin resistance in MCF-7/ADR breast cancer cells as a selective topoisomerase IIα inhibitor. Naunyn Schmiedeb. Arch. Pharmacol.395 (1), 6576. 10.1007/s00210-021-02172-5

  • 67

    LuoR.ChenX.MaH.YaoC.LiuM.TaoJ.et al (2019). Myocardial caspase-3 and NF-κB activation promotes calpain-induced septic apoptosis: The role of Akt/eNOS/NO pathway. Life Sci.222, 195202. 10.1016/j.lfs.2019.02.048

  • 68

    MaF. M.YuT. Q. (2018). Effects of benzoylmesaconin on proliferation and apoptosis of human multipe myeloma cell RPMI-8226. J. Jinan Univ. Sci. Med. Ed.39 (06), 481487.

  • 69

    MaL.GuR.TangL.ChenZ. E.DiR.LongC. (2015). Important poisonous plants in Tibetan ethnomedicine. Toxins (Basel)7 (1), 138155. 10.3390/toxins7010138

  • 70

    MaX. F. (2017). Aconitine regulates the EMT microenvironment to reduce the lung cancer maligant. Zhengzhou: Henan University, 78.

  • 71

    MaheswariU.GhoshK.SadrasS. R. (2018). Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells. Apoptosis23 (3-4), 210225. 10.1007/s10495-018-1449-8

  • 72

    MaiuriM. C.ZalckvarE.KimchiA.KroemerG. (2007). Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell. Biol.8 (9), 741752. 10.1038/nrm2239

  • 73

    OeckinghausA.GhoshS. (2009). The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol.1 (4), a000034. 10.1101/cshperspect.a000034

  • 74

    OnoratiA. V.DyczynskiM.OjhaR.AmaravadiR. K. (2018). Targeting autophagy in cancer. Cancer124 (16), 33073318. 10.1002/cncr.31335

  • 75

    QiX.WangL.WangH.YangL.LiX.WangL. (2018a). Aconitine inhibits the proliferation of hepatocellular carcinoma by inducing apoptosis. Int. J. Clin. Exp. Pathol.11 (11), 52785289.

  • 76

    QiX.WangL.WangH.YangL.LiX.WangL. (2018b). Aconitine inhibits the proliferation of hepatocellular carcinoma by inducing apoptosis. Int. J. Clin. Exp. Pathol.11 (11), 52785289.

  • 77

    RaimundoL.CalheirosJ.SaraivaL. (2021). Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target. Cancers (Basel)13 (14). 10.3390/cancers13143438

  • 78

    RaoZ. L.PengC. (2010). Study on the effect of aconitic alkaloid on ras gene expression and its molecular mechanism of antitumor activity. Mod. Prev. Med.37 (06), 10981100+1103.

  • 79

    RascioF.PontrelliP.GrandalianoG. (2021). Cytotoxic T lymphocytes (CTLs) and kidney transplantation: An overview. Methods Mol. Biol.2325, 203213. 10.1007/978-1-0716-1507-2_14

  • 80

    ReardonM. J. (2010). Malignant tumor overview. Methodist Debakey Cardiovasc J.6 (3), 3537. 10.14797/mdcj-6-3-35

  • 81

    ReinboltR. E.ManginiN.HillJ. L.LevineL. B.DempseyJ. L.SingaraveluJ.et al (2015). Endocrine therapy in breast cancer: The neoadjuvant, adjuvant, and metastatic approach. Semin. Oncol. Nurs.31 (2), 146155. 10.1016/j.soncn.2015.02.002

  • 82

    RenL. Y.ZengS. P. (2008). Effect of radix aciniti praeparata extract on cell apoptosis in transplanted liver cancer H22. Henan Tradit. Chin. Med. (11), 3437.

  • 83

    RodewaldH. R. (2008). Thymus organogenesis. Annu. Rev. Immunol.26, 355388. 10.1146/annurev.immunol.26.021607.090408

  • 84

    RuJ.ChenZ.DengM.LiM. H.ZhangS. (2020). Aconitine induces apoptosis and inhibits proliferation of gastric adenocarcinoma cell line MGC803 by down-regulating miR-23a. Chin. J. Ethnomedicine Ethnopharmacy29 (24), 1217.

  • 85

    SahaS.ButtariB.PanieriE.ProfumoE.SasoL. (2020). An overview of Nrf2 signaling pathway and its role in inflammation. Molecules25 (22). 10.3390/molecules25225474

  • 86

    SangaranP. G.IbrahimZ. A.ChikZ.MohamedZ.AhmadianiA. (2021). LPS preconditioning attenuates apoptosis mechanism by inhibiting NF-κB and caspase-3 activity: TLR4 pre-activation in the signaling pathway of LPS-induced neuroprotection. Mol. Neurobiol.58 (5), 24072422. 10.1007/s12035-020-02227-3

  • 87

    SchneiderA. T.GautheronJ.FeoktistovaM.RoderburgC.LoosenS. H.RoyS.et al (2017). RIPK1 suppresses a TRAF2-dependent pathway to liver cancer. Cancer Cell.31 (1), 94109. 10.1016/j.ccell.2016.11.009

  • 88

    SchreckR.BaeuerleP. A. (1990). NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol. Cell. Biol.10 (3), 12811286. 10.1128/mcb.10.3.1281-1286.1990

  • 89

    SenaE.van der WorpH. B.HowellsD.MacleodM. (2007). How can we improve the pre-clinical development of drugs for stroke?Trends Neurosci.30 (9), 433439. 10.1016/j.tins.2007.06.009

  • 90

    ShaoX.HanB.JiangX. H.LiF.HeM.LiuF. (2019). Effects of benzoyl aconitine on autophagy and apoptosis of human lung cancer cell line in A549. China Pharm.30 (20), 27822788.

  • 91

    SiddiquiW. A.AhadA.AhsanH. (2015). The mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update. Arch. Toxicol.89 (3), 289317. 10.1007/s00204-014-1448-7

  • 92

    SmaleS. T. (2012). Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors. Immunol. Rev.246 (1), 193204. 10.1111/j.1600-065X.2011.01091.x

  • 93

    SonensheinG. E. (1997). Rel/NF-kappa B transcription factors and the control of apoptosis. Semin. Cancer Biol.8 (2), 113119. 10.1006/scbi.1997.0062

  • 94

    SuhailY.CainM. P.VanajaK.KurywchakP. A.LevchenkoA.KalluriR.et al (2019). Systems biology of cancer metastasis. Cell. Syst.9 (2), 109127. 10.1016/j.cels.2019.07.003

  • 95

    SunY.PangB.WangY.XiaoJ.JiangD. (2021). Baohuoside I inhibits the proliferation of hepatocellular carcinoma cells via apoptosis signaling and NF-kB pathway. Chem. Biodivers.18 (6), e2100063. 10.1002/cbdv.202100063

  • 96

    TangM. X.SunG. Z. (1986). Study on the anti tumor and anti metastasis of aconitine and observation on the treatment of cancer. Beijing J. Traditional Chin. Med. (03), 2728.

  • 97

    TommeleinJ.De VlieghereE.VersetL.MelsensE.LeendersJ.DescampsB.et al (2018). Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res.78 (3), 659670. 10.1158/0008-5472.CAN-17-0524

  • 98

    VasudevanK. M.GurumurthyS.RangnekarV. M. (2004). Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol.24 (3), 10071021. 10.1128/MCB.24.3.1007-1021.2004

  • 99

    WangC. F.GernerP.SchmidtB.XuZ. Z.NauC.WangS. Y.et al (2008). Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat. Anesth. Analg.107 (4), 13971405. 10.1213/ane.0b013e318182401b

  • 100

    WangH. (2020). Experimental study on the function of anti hepatoma and immunoregulation of aconite. Shanghai: Naval Medical University, 92.

  • 101

    WangH.LiuY.GuoZ.WuK.ZhangY.TianY.et al (2022). Aconitine induces cell apoptosis via mitochondria and death receptor signaling pathways in hippocampus cell line. Res. Vet. Sci.143, 124133. 10.1016/j.rvsc.2022.01.001

  • 102

    WangX.LinY.ZhengY. (2020). Antitumor effects of aconitine in A2780 cells via estrogen receptor β‑mediated apoptosis, DNA damage and migration. Mol. Med. Rep.22 (3), 23182328. 10.3892/mmr.2020.11322

  • 103

    WangY.ShanY.WangY.FangY.HuangT.WangS.et al (2019). Aconitine inhibits androgen synthesis enzymes by rat immature Leydig cells via down-regulating androgen synthetic enzyme expression in vitro. Chem. Biol. Interact.312, 108817. 10.1016/j.cbi.2019.108817

  • 104

    WarrenC.Wong-BrownM. W.BowdenN. A. (2019). BCL-2 family isoforms in apoptosis and cancer. Cell. Death Dis.10 (3), 177. 10.1038/s41419-019-1407-6

  • 105

    WuJ. T.KralJ. G. (2005). The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. J. Surg. Res.123 (1), 158169. 10.1016/j.jss.2004.06.006

  • 106

    WuJ.ZhuY.GuoZ.LouY.HeS.GuanY.et al (2018). Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway. Phytomedicine44, 8797. 10.1016/j.phymed.2017.12.007

  • 107

    WuX.YuanM. M.XiongX. L.ZhongG. H. (2021). Advances in the study of chemical constituents and pharmacological effects of aconiti kusnezoffii radix. Drug Eval.18 (24), 15341536.

  • 108

    WulijiT. G. S.LiuZ. B.WangH. S.DingY. X.SuY. F. (2008). Effect of total alkaloids from kusnezoff monkshood leaves on immune function in mice. Chin. Traditional Herb. Drugs (07), 10641065.

  • 109

    XiongH. S.JiangC.GaoR.ChenL. H. (2018). Regulatory effects and mechanism of aconitine on proliferation, invasion and migration of hepatoma carcinoma cell MHCC97. Chin. J. Immunol.34 (05), 688692.

  • 110

    XuX. F.PiH. F.YangJ.ZhuT.RuanH. L.ZhangY. H.et al (2008). A preliminary study on the antitumor cell proliferation activity of aconitum sheath stalk in vitro. Her. Med. (08), 918.

  • 111

    YaidikarL.ThakurS. (2015). Punicalagin attenuated cerebral ischemia-reperfusion insult via inhibition of proinflammatory cytokines, up-regulation of Bcl-2, down-regulation of Bax, and caspase-3. Mol. Cell. Biochem.402 (1-2), 141148. 10.1007/s11010-014-2321-y

  • 112

    YangL.ChenY.ZhouJ.SunJ.JiangW.LiuT.et al (2021). Aconitine induces mitochondrial energy metabolism dysfunction through inhibition of AMPK signaling and interference with mitochondrial dynamics in SH-SY5Y cells. Toxicol. Lett.347, 3644. 10.1016/j.toxlet.2021.04.020

  • 113

    YangL. H.LinL. M.WangZ. M.LiC.LiZ. (2016). [Advance on chemical compounds of Tibetan medicinal plants of Aconitum genus]. Zhongguo Zhong Yao Za Zhi41 (3), 362376. 10.4268/cjcmm20160302

  • 114

    YangQ.NieS. Q.WengX. G.LiL. F.HuangL. Q. (2005). Experiment studies on anti-tumor effect in vivo and in vitro of aconitum carmichaelii debx. And fritillaria thunbergii MiQ. Used singly or matched. Chin. J. Exp. Traditional Med. Formulae (04), 2528.

  • 115

    YaoF.JiangG. R.LiangG. Q.YuanQ.ZhuY.LiuM.et al (2021). The antitumor effect of the combination of aconitine and crude monkshood polysaccharide on hepatocellular carcinoma. Pak. J. Pharm. Sci.34 (3), 971979.

  • 116

    YeQ.LiuJ.XieK. (2019). Zinc finger proteins and regulation of the hallmarks of cancer. Histol. Histopathol.34 (10), 10971109. 10.14670/HH-18-121

  • 117

    ZengJ.LuoX.JiangN.QingY.XuX. Y.YuM. Y. (2007). Study on tumor-inhibitory effect of ChuanWu aqueous extract. J. Sichuan Univ. Sci. Ed. (06), 13441348.

  • 118

    ZhangB. Y. (2021). A report on the translation of health without borders: Epidemics in the era of globalization (chapter 5-7). Chongqing: Sichuan International Studies University, 97.

  • 119

    ZhangL. J.TangX. E.YaoM. Q.LiuY.ZhaoF. C. (2018). Investigation of the toxicity of three alkaloids in Junggar aconitumon H9c2 cells. J. Xinjiang Med. Univ.41 (11), 13911395.

  • 120

    ZhangL. J.ZhaoS. J.DengR. F.ZhaoF. C. (2020). Studies on A549 cytotoxicity of aconitine alkaloids and its hydrolyzed products in junggar. China Pharm.23 (02), 252255.

  • 121

    ZhangL.SiyitiM.ZhangJ.YaoM.ZhaoF. (2021). Anti‑inflammatory and anti‑rheumatic activities in vitro of alkaloids separated from Aconitum soongoricum Stapf. Exp. Ther. Med.21 (5), 493. 10.3892/etm.2021.9924

  • 122

    ZhangQ.ChenX.LuoY.RenH.QiaoT. (2017). Fuzi enhances anti-tumor efficacy of radiotherapy on lung cancer. J. Cancer.8 (19), 39453951. 10.7150/jca.22162

  • 123

    ZhangR. (2021). Aconitine and PolyIC promote T cell development underlying their anti-tumor effect. Lanzhou: Lanzhou University, 77.

  • 124

    ZhangW.ShuH.FangL.TangN.LiY.GuoB.et al (2020). Cancer inhibition mechanism of lung cancer mouse model based on dye trace method. Saudi J. Biol. Sci.27 (4), 11551162. 10.1016/j.sjbs.2019.12.040

  • 125

    ZhangW.ZhangyuanG.WangF.JinK.ShenH.ZhangL.et al (2021). The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity54 (6), 1168e8. 10.1016/j.immuni.2021.04.027

  • 126

    ZhangX. D.WuY. T. (2011). Study on apoptosis induction by aconite root in SGC-7901 gastric cancer cell. J. Zhejiang Chin. Med. Univ.35 (05), 665668.

  • 127

    ZhaoB.HouX. D.LiH.QiX. X.LiG. G.LiuL. X.et al (2014). [Comparative study of Coptidis Rhizoma and Aconiti Kusnezoffii Radix on cell differentiation in lewis lung cancer]. Zhongguo Zhong Yao Za Zhi39 (14), 27322738.

  • 128

    ZhaoH.WuL.YanG.ChenY.ZhouM.WuY.et al (2021). Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct. Target. Ther.6 (1), 263. 10.1038/s41392-021-00658-5

  • 129

    ZhengS. C.YanX. Y.ChenJ.ZhaoS. T.WenC. B. (2017). [Anti-inflammatory mechanism analysis of antirheumatic Chinese medicinal herb Aconiti Radix based on protein interaction network]. Zhongguo Zhong Yao Za Zhi42 (9), 17471751. 10.19540/j.cnki.cjcmm.20170121.031

  • 130

    ZhouX. J.LiY. H.TangX.LvY. B.ZhouJ. L. (2019). Aconitine inhibits the proliferation and invasion while induces the apoptosis of esophageal cancer EC-1 cells. Chin. Med. Biotechnol.14 (04), 335340.

  • 131

    ZhouY. P.LiuW. H.ZengG. Y.ChenD. H.LiH. Y.SongW. L. (1984). The toxicity of aconitine and its analogues and their effects on cardiac contractive function. Acta Pharm. Sin. (09), 641646.

  • 132

    ZhuT. (2008). Studies on the antitumor constituents of aconitum vaginatum. Wuhan: Huazhong University of Science and Technology, 79.

  • 133

    ZouF.LiL. L.DaiM.NieT.LiuH. C. (2021). Study on the mechanism of aconitine inducing apoptosis of osteosarcoma cells through ROS/JNK signal transduction pathway. Jiangxi Med. J.56 (06), 799802.

  • 134

    ZussoM.LunardiV.FranceschiniD.PagettaA.LoR.StifaniS.et al (2019). Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J. Neuroinflammation16 (1), 148. 10.1186/s12974-019-1538-9

Summary

Keywords

aconitine, malignancy, preclinical studies, meta-analysis, bax, NF-κB, bcl-2

Citation

Xiang G, Xing N, Wang S and Zhang Y (2023) Antitumor effects and potential mechanisms of aconitine based on preclinical studies: an updated systematic review and meta-analysis. Front. Pharmacol. 14:1172939. doi: 10.3389/fphar.2023.1172939

Received

24 February 2023

Accepted

17 April 2023

Published

27 April 2023

Volume

14 - 2023

Edited by

Muhammad Riaz, Shaheed Benazir Bhutto University, Pakistan

Reviewed by

Yi Li, China Pharmaceutical University, China

Hua Yang, China Pharmaceutical University, China

Updates

Copyright

*Correspondence: Shaohui Wang, ; Yi Zhang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics